

BMJ Open

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013402
Article Type:	Research
Date Submitted by the Author:	13-Jul-2016
Complete List of Authors:	Saunders, Rhodri; Coreva Scientific GmbH & Co. KG. Struys, Michel; University of Groningen, Department of Anesthesiology Pollock, Richard; Ossian Health Economics and Communications GmbH, Mestek, Michael; Medtronic Inc, Patient Monitoring & Recovery Lightdale, Jenifer; UMass Memorial Children's Medical Center, Pediatric Gastroenterology
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Surgery
Keywords:	Capnography, Meta-analysis, Procedural sedation, Ambulatory surgery
<p>Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.</p> <p>Capnography Meta-analysis BMJ PRISMA 2009 checklist.docx</p>	

SCHOLARONE™
Manuscripts

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY**MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Authors: Rhodri Saunders DPhil^{1,2}, Michel MRF Struys MD PhD FRCA (Hon)³,
Richard F Pollock MA MSci², Michael Mestek PhD⁴, Lightdale JR MD MPH⁵

Affiliations: ¹ Coreva Scientific GmbH & Co. KG., Freiburg, Germany
² Ossian Health Economics and Communications, Basel, Switzerland
³ Department of Anesthesiology, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands; Department of
Anesthesia, Ghent University, Gent, Belgium
⁴ Medtronic, Patient Monitoring & Recovery, Boulder, CO
⁵ Pediatric Gastroenterology, UMass Memorial Children's Medical Center,
Worcester, MA; University of Massachusetts Medical School, Worcester,
MA

Corresponding author: Richard Pollock MA MSci
Ossian Health Economics and Communications GmbH,
Bäumleingasse 20,
4051 Basel, Switzerland
+41 61 271 62 14
pollock@ossianconsulting.com

Word count: 3,572

Running title: Patient safety during sedation: a meta-analysis

Key words: Capnography; Respiratory compromise; Oxygen desaturation; Apnea;
Assisted ventilation;

Target journal: BMJ

Grant support: This study was supported by funding from Medtronic plc.

ABSTRACT

Objective

To evaluate the effect of capnography monitoring on sedation-related adverse events during PSA administered during ambulatory surgery relative to visual assessment and pulse oximetry alone.

Design and Setting

Systematic literature review and random effects meta-analysis of randomized controlled trials (RCTs) reporting sedation-related adverse event incidence when adding capnography to visual assessment and pulse oximetry in patients undergoing PSA during ambulatory surgery in the hospital setting. Searches for eligible studies published between 1995 and 2015 (inclusive) were conducted in PubMed, the Cochrane Library and EMBASE without any language constraints. Searches were conducted in June, 2015.

Interventions

Capnography monitoring relative to visual assessment and pulse oximetry alone.

Primary and Secondary Outcome Measures

Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint), apnea, aspiration, bradycardia, hypotension, premature procedure termination, respiratory failure, use of assisted/bag-mask ventilation and death during PSA.

Results

The literature search identified 861 unique articles, of which 11 were ultimately included in the meta-analysis. Addition of capnography to visual assessment and pulse oximetry was associated with a significant reduction in the incidence of apnea (OR 0.49, 95% CI 0.32–0.75), as well as mild (OR 0.54, 95% CI 0.44–0.66) and severe (OR 0.49, 95% CI 0.34–0.71) desaturation. Reduced occurrence of assisted ventilation was also observed with capnography, but this did not reach significance.

Conclusions

Meta-analysis of 11 RCTs published between 2006 and 2015 showed a reduction in respiratory compromise during PSA with the inclusion of capnography monitoring. In particular, use of capnography was associated with less mild and severe oxygen desaturation, and may help to avoid the need for assisted ventilation.

STRENGTHS AND LIMITATIONS OF THIS STUDY

Strengths

- The studies included in the analysis were all published in 2006 or later, representing modern medical practice and providing consistent evidence of improvements in patient safety with the use of capnography monitoring.
- The study findings further substantiate a previously-published meta-analysis, which found that capnography monitoring was more likely to detect adverse events.

Limitations

- The level of sedation employed in each study was not uniformly reported, resulting in a mixture of different sedation levels in the primary analysis and precluding an analysis of outcomes by sedation level.
- As with all meta-analyses, the study findings may be affected by publication, search or selection bias affecting the studies ultimately included in the analysis; however, where possible, steps were taken to minimize the effects of bias on the analysis, but the degree to which these steps were successful is difficult to quantify.

BACKGROUND AND AIMS

The administration of procedural sedation and analgesia (PSA) involves achieving a drug-induced depression in level of consciousness and pain to ensure the comfort and cooperation of patients undergoing non-surgical procedures. Significant adverse events associated with PSA are relatively rare but not inconsequential, and can include severe oxygen desaturation, bradycardia, hypotension, and cardiac arrest.^{1,2} Consensus dictates that levels of sedation are directly related to patient risk during PSA, as is the potential for unintended progression from moderate to deep sedation.³ Generally speaking, most cardiopulmonary events associated with PSA stem from poor or absent ventilation cascading into hypoxia, tissue injury and cardiac decompensation (Supplement, Figure 3). In turn, maintaining patient safety involves the identification of respiratory compromise to prompt the use of clinical intervention before further complications occur.^{4,5,6,7,8,9}

In current clinical practice, patient monitoring during PSA often relies on visual assessment of ventilation and use of pulse oximetry, which reflects hypoxemia.^{10,11,12,13,14} To date, a mandate to include capnography in patient monitoring, as a means of early detection of alveolar hypoventilation, has remained a topic of debate.¹⁵ In particular, there has been a perceived gap between various study outcomes and evidence of improved patient safety. No studies have provided “hard proof” that addition of capnography to patient monitoring may reduce severe morbidity and mortality during PSA (in part because of ethical considerations to ensure patient rescue), and efforts to use meta-analysis to determine the utility of capnography to identify clinically significant respiratory depression have been faulted for large heterogeneity and non-standard endpoints.^{16,17}

The primary aim of the present systematic review and meta-analysis was to understand whether capnography added to patient monitoring only (consisting of pulse oximetry and visual inspection of ventilation) reduces the incidence of adverse events during PSA based on randomized controlled trials of patients undergoing a variety of surgical procedures. As a secondary aim, a power calculation was performed to determine the number of patients that would be required to demonstrate a reduction in

1
2
3 patient harm, defined as severe morbidity or mortality, in a prospective clinical trial of capnography
4
5 versus visual assessment with pulse oximetry. The analysis was based on the hypothesis that earlier
6
7 and more sensitive detection of ventilatory changes with capnography may allow for more timely
8
9 intervention and prevention of potential adverse events, such as cardiac dysrhythmias. Throughout the
10
11 analyses, we sought to provide the highest level of synthesized evidence with respect to the clinical
12
13 utility of capnography monitoring during PSA. To mitigate potential pitfalls due to non-standard
14
15 endpoints, particular emphasis was placed on maintaining a consistent definition of adverse events
16
17 across all studies included.
18
19

20 21 **METHODS**

22
23 Literature searches were conducted in PubMed, the Cochrane Library and EMBASE. Search terms were
24
25 a combination of Medical Subject Heading (MeSH) terms and free-text searches within the articles title
26
27 and abstract. Searches aimed to identify all literature reporting on randomized, controlled trials in
28
29 patients receiving sedation during ambulatory surgery and in which visual assessment of ventilation
30
31 and pulse oximetry monitoring (control) was compared with control plus capnography. No review
32
33 protocol was registered in advance, but the full search strategy (Supplement, Table 3) and further
34
35 details are provided in the Supplement. Only articles or abstracts published on or after January 1, 1995
36
37 were included and all searches were performed on June 17, 2015. No language exclusion was applied
38
39 and inclusion was not dependent on the capnography monitor in use. After duplicate removal, title
40
41 and abstract screening (Supplement, Table 4) was performed independently by RS and RFP. Full-text
42
43 versions of all non-excluded articles were retrieved by MM and reviewed independently by RS and
44
45 RFP. Data were then extracted independently by RS and RFP into data extraction forms in Microsoft
46
47 Excel (Microsoft Corporation, Redmond, WA). Any discrepancies in the extracted data were resolved
48
49 by reference to the original study, reaching consensus between RS and RFP. All extracted endpoint
50
51 data were reviewed by JL and MMS for clinical utility to ensure that all synthesized data relate to
52
53
54
55
56
57
58
59
60

1
2
3 clinically equivalent endpoints. Extracted data included the number of patients with events and the
4
5 population at risk, in addition to items required to assess article quality and bias.
6
7

8 **Endpoints**

9
10 Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint), apnea,
11
12 aspiration, bradycardia, hypotension, premature procedure termination, respiratory failure, use of
13
14 assisted/bag-mask ventilation and death during PSA. The protocol was left open for the analysis of
15
16 other patient safety endpoints that were reported by ≥ 3 studies. Cardiac arrest and death were
17
18 considered to be representative of severe morbidity and mortality.
19
20

21 **Quality and potential bias**

22
23 Assessment of article quality was conducted on a study (as opposed to outcome) level using a
24
25 modified Jadad scale,¹⁸ with additional criteria added to make the adaptation specific to monitoring.
26
27 The Jadad scale scores articles on their design (randomized and blinded) and their reporting (all
28
29 patients accounted for), with a maximal score of 5 (high quality) and a low score of 0 (low quality).
30
31 Additional data included here were endpoint definitions, patient population, hospital location at which
32
33 patients underwent sedation, and the staff responsible for monitoring. In keeping with Jadad, items
34
35 related to trial design could score up to twice as highly as items relating to trial reporting. The
36
37 reporting of the inclusion/exclusion criteria and endpoint definitions scored one point each, and
38
39 reporting the location of sedation, and the monitoring staff scored half-point point each, making the
40
41 maximal score 8 (high quality). For the purposes of analyzing study quality, studies with scores of 0–5
42
43 were considered to be low quality, while studies scoring 5.5–8 were designated as high quality studies.
44
45
46
47 Risk of bias in results was evaluated through the declaration of funding sources and conflicts of
48
49 interest. If the study was funded by industry then the study scored 2, any conflicts of interest declared
50
51 relating to industry funding outside of the current research publication scored 1. A study with low
52
53 potential for bias, therefore, would have a score of 0. A high potential for bias was defined as a score
54
55 of 3, while a score of 1–2 was considered to indicate moderate potential for bias.
56
57
58
59
60

Analysis

Data extraction, initial data consolidation and summary statistics were performed in Microsoft Excel.

Data for each endpoint were subsequently entered into Review Manager 5.3.4 for results synthesis.¹⁹

Heterogeneity of data was evaluated using Chi^2 and I^2 statistics presented by Review Manager 5.3.4.

The meta-analysis performed calculated the mean intervention effect across all eligible studies using (after analysis of heterogeneity) a random effects model as described by DerSimonian and Laird.²⁰ An

estimate of between-study variation was provided by the Mantel-Haenszel methodology.²¹ The

outcome reported for each endpoint is the pooled mean odds ratio (OR) and its 95% confidence interval.

For sensitivity analyses, the tested conditions were: (1) inclusion of only moderate sedation, (2) inclusion of only studies with low risk of bias, (3) inclusion of only studies based in the US, (4) inclusion of only studies based in Europe, (5) exclusion of pediatric data, (6) exclusion of gender-specific studies, (7) exclusion of data in patients <30 years of age.

Patient involvement

No patients, service users, carers or lay people were involved in the design or conduct of this study.

Outcome measures were all related to patient safety during PSA, but were not developed based on an explicit elicitation of patient priorities, experience, and preferences.

RESULTS

Literature searches of PubMed, the Cochrane Library and EMBASE returned 353, 76, and 672 articles, respectively. After removal of 240 duplicates (55 Cochrane, 185 EMBASE), 861 articles remained for abstract screening. Although reasons for exclusion varied (Supplement, Table 4), the two independent reviewers agreed upon a total of 19 articles to be retained for full-text review (Cohen's kappa, 1.0).

Eight articles were excluded on full-text review (Supplement, Figure 4) because they: reported duplicate data (n=3), did not report patient safety data (N=3), and did not include sedation (n=2). The

1
2
3 11 articles included for analysis are presented in Table 1. All studies reported desaturation endpoints,
4
5 although the definition did vary by study (Supplement, Table 5). Other endpoints were
6
7 heterogeneously reported, but were in most cases reported by ≥ 3 studies making meta-analysis
8
9 feasible. Results reported are from random-effects models unless otherwise stated. Results for
10
11 hypotension and use of supplemental oxygen are provided in the Supplement.
12

13 **Mild desaturation**

14
15
16 All studies reported mild desaturation, with the definition varying from an oxygen saturation (SpO_2) of
17
18 $<95\%$ to $<90\%$ for ≥ 15 seconds. In the primary analysis of high quality studies ($n=8$), there was little
19
20 evidence of heterogeneity ($I^2 = 11\%$) and the mean OR did not differ between random-effects and
21
22 fixed-effects models. Results indicated that capnography significantly reduced the incidence of mild
23
24 desaturation (OR = 0.54, 95% CI 0.44–0.66; Figure 1). As such, a mild desaturation event is
25
26 approximately half as likely to occur if capnography monitoring is used, compared with no use of
27
28 capnography. If all available data were included (Supplement, Figure 5), there was evidence of
29
30 significant heterogeneity ($I^2 = 49\%$) with an OR of 0.65 (95% CI 0.51–0.81). Using exclusively studies
31
32 with equivalent definitions of mild desaturation ($<90\%$, $n=6$), evidence of heterogeneity ($I^2 = 47\%$) is
33
34 still present. The OR estimated from these studies was 0.60 (95% CI 0.46–0.77).
35
36
37

38 **Severe desaturation**

39
40
41 Six studies, of which three were classified as high quality, reported severe desaturation. All but one of
42
43 the studies defined severe desaturation as $\text{SpO}_2 < / \leq 85\%$. The primary analysis for this endpoint
44
45 returned an OR of 0.49 (95% CI 0.34–0.71), further supporting the significant reduction in desaturation
46
47 incidence with the inclusion of capnography (Figure 1). As with mild desaturation, there was no
48
49 evidence of heterogeneity in the three high-quality studies ($I^2 = 0\%$) and the OR was consistent
50
51 between random-effects and fixed-effects models.
52

53
54
55 Synthesizing estimates from all available data supported the primary analysis (Supplement, Figure 6),
56
57 the OR was reduced by 0.02 and the confidence interval tightened (OR 0.47, 95% CI 0.34–0.66). There
58
59
60

1
2
3 was no significant heterogeneity between studies ($I^2 = 16\%$). Focusing on the five studies reporting an
4
5 endpoint of SpO₂ $\leq 85\%$, there was no heterogeneity and the OR was estimated at 0.44 (95% CI
6
7 0.32–0.60). Overall, results support a greater than 50% reduction in the incidence of severe
8
9 desaturation events if capnography monitoring is used.
10

11 **Apnea**

12
13 Apnea was less widely reported or reported in combination with disordered respiration. Comparable
14
15 endpoints were reported by four studies, of which two were high quality. Primary analysis
16
17 demonstrated a significant reduction in apnea with capnography monitoring (OR 0.49, 95% CI 0.32–
18
19 0.75), with no evidence of heterogeneity (Supplement, Figure 7). If all studies were included the
20
21 degree of heterogeneity became significant ($I^2 = 75\%$) and the outcome lacked significance at the 5%
22
23 level (OR 0.75, 95% CI 0.43–1.33). The degree of between study heterogeneity supported the use of a
24
25 random-effects model, analysis using a fixed effects model did not change the estimated OR but did
26
27 restrict the 95% CI to 0.57–0.99. The difference between the primary and secondary analyses for this
28
29 endpoint was driven by the study of Kochhar et al., which found apnea to be increased in the
30
31 capnography arm.
32
33
34
35

36 **Bradycardia**

37
38 Three studies, all of high-quality, reported bradycardia outcomes. Its definition (heart rate < 50
39
40 beats/minute) was consistent among trials and there was no evidence of between study heterogeneity
41
42 ($I^2 = 0\%$). In all studies, the incidence of bradycardia was higher in the capnography arm compared
43
44 with the control arm (Supplement, Figure 8). Overall, capnography monitoring was associated with a
45
46 non-significant increase in bradycardia (OR 1.23, 95% CI 0.87–1.74).
47
48
49

50 **Assisted ventilation**

51
52 Only one study reported one instance of what they termed “respiratory failure,” that was treated with
53
54 assisted bag-mask ventilation. In contrast, the number of studies reporting assisted and/or bag-mask
55
56 ventilation was sufficient to perform a meta-analysis of this endpoint as a surrogate for respiratory
57
58
59
60

1
2
3 failure. In total, five studies reported this and all were classified as high-quality. The primary analysis
4
5 returned no evidence of heterogeneity and an OR of 0.83 (95% CI 0.59–1.17). In every case, the need
6
7 to provided assisted ventilation was lower in the capnography arm compared with the control arm
8
9 (Figure 2). The lack of significance reflects the low number of observed events and the subsequent
10
11 potential for error.
12

13 **Sensitivity analyses**

14
15 A series of sensitivity analyses were conducted in which the studies included in the estimation of the
16
17 OR were varied. The results of these analyses are presented in Table 2 and show that results are
18
19 generally robust to the studies included for data synthesis. There were limited data available to assess
20
21 the impact of capnography monitoring during moderate sedation. Data available indicate that the
22
23 impact of capnography is reduced relative to deep sedation. With respect to severe desaturation
24
25 events, there was also a substantial difference between US and European data. In Europe, addition of
26
27 capnography monitoring was estimated to reduce the incidence of severe desaturation by about 40%.
28
29 For the US based studies this increased to 65%, meaning that almost 2 in 3 severe desaturation events
30
31 were avoided.
32
33
34
35

36
37 Patient safety concerns often focus on mortality and severe morbidity. There was no evidence that
38
39 these outcomes differ between control and capnography arms in the present meta-analysis. The
40
41 incidence of these events during nurse-administered PSA has been reported to be 1 event per 303
42
43 procedures (0.33%).²² Taking this value and using the assumption that capnography could prevent
44
45 50% of events, the formula provided by Zhong (2009) to calculate the trial size required to
46
47 demonstrate statistical superiority returned 27,726 patients.²³ Switching to an assumption that
48
49 capnography would prevent 10% of events, the required trial size was calculated to be >900,000
50
51 patients.
52
53
54
55
56
57
58
59
60

DISCUSSION

The findings of a meta-analysis of recent RCTs comparing visual assessment of ventilation and pulse oximetry monitoring with and without capnography during PSA showed that the incidence of apnea and oxygen desaturation events were significantly reduced with the use of capnography. Other endpoints that could be affected by capnography monitoring were also considered and the majority was found to be associated with substantial, but not significant, benefits to patient safety. Specifically, and of potential clinical importance, was the consistency of data across multiple high-quality clinical trials reporting a reduced incidence of assisted ventilation with capnography monitoring. No endpoints assessed in the meta-analysis indicated significant patient safety concerns with capnography. In addition, sensitivity analyses suggested that a clinical trial designed to test for a significant difference in patient harm with use of capnography would require an unfeasibly large number of patients. Not only is the feasibility of performing such a superiority trial low, but meta-analyses such as the present study, are not able to detect this difference from the relatively small number of existing lower-powered studies currently available in peer-reviewed medical literature.

The analysis is timely given the ongoing lively debate as to whether the addition of capnography to patient monitoring during PSA adds value.¹⁷ Without doubt, potential technical and financial burdens have further limited adoption of capnography monitoring in various clinical settings.^{15,17} Nevertheless, it is important to recognize that patient safety benefits may offset a number of these concerns if the outcomes are applicable to current medical practice.²⁴ In this regard, the 11 trials identified in the present analysis were all relatively recent, with the first published study identified in 2006. The data used in the meta-analysis therefore represents modern medical practice, and provides consistent evidence of improvements in patient safety with the use of capnography monitoring.

These findings further substantiate a previously published meta-analysis (Waugh *et al.*), which found that capnography monitoring was more likely to detect adverse events, but was faulted for large endpoint heterogeneity.¹⁶ In the present meta-analysis, we focused on identifying high-quality studies,

1
2
3 and on maintaining consistent definitions across all included studies, thereby minimizing potential for
4 heterogeneity. The results show that the addition of capnography to patient monitoring during PSA
5 results in increased patient safety, with significant reductions in apnea, as well as mild and severe
6 levels of oxygen desaturation.
7
8
9

10
11 More recently, a meta-analysis by Conway *et al.* reported a significant benefit with capnography
12 during colonoscopy only with respect to hypoxemia. However, the study identified and screened only
13 a fraction of the literature included in the present analysis (388 papers in Conway *et al.*, compared with
14 861 papers in the current study) and retrieved fewer randomized controlled trials (6 versus 11). In
15 addition, Conway *et al.* excluded two trials in which an independent observer monitored capnography
16 output for all patients, and signaled to the attending physician when respiratory compromise was
17 identified with capnography either immediately (intervention) or after a specified delay (control).^{5,6} The
18 rationale for this was to prevent unnecessary patient harm while avoiding investigator bias. Based on
19 our understanding, the two trials that Conway and colleagues excluded are, contrary to expectation,
20 the only studies in the literature that could be considered fully blinded. Among the other studies, the
21 attending physician would have been aware of study arm assignment.^{32,38,42} The results of the Conway
22 analysis should therefore be interpreted with caution. Nevertheless, the finding of consistent
23 outcomes for hypoxemia in Conway *et al.* (relative risk 0.59, 95% CI 0.48 to 0.73) and mild desaturation
24 in the present analysis (OR 0.54, 95% CI 0.44 to 0.66; RR 0.65, 95% CI 0.57 to 0.74) was encouraging.
25 These findings are also aligned with a European randomized, controlled trial of capnography that was
26 published after the analysis was complete.²⁵
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Yet another ongoing debate in PSA concerns the clinical importance of seemingly minor endpoints,
48 such as mild desaturation (oxygenation <90% for 15 seconds). Although such endpoints may be
49 transient and perhaps clinically insignificant, several recent studies have suggested that mild
50 desaturation, as a common intraoperative event, may have an impact on post-surgical outcomes.²⁶
51 For example, one retrospective study determined that patients who experienced perioperative
52 hypoxemia/desaturation had a significant increase in their length of hospital stay (+2.0 days,
53
54
55
56
57
58
59
60

1
2
3 $p < 0.0001$).²⁷ The long-term importance of these endpoints in terms of patient outcomes and quality
4 of life remains unknown.
5
6

7
8 Over all of the studies included in the analysis, there were no reports of patient mortality. Only the
9 largest trials reported any requirement for assisted/bag-mask ventilation, which is used as an
10 intervention and thereby a proxy measure for potentially life-threatening events. Although it is
11 generally accepted that much larger studies would be useful to assess whether or not capnography
12 monitoring impacts patient major morbidity and mortality, there has been no determination of the
13 trial size that would be required. Power calculations suggest such a large randomized controlled trial is
14 likely to be impractical.
15
16
17
18
19
20
21

22
23 For healthcare providers, the most significant finding may be the consistency of data surrounding
24 apnea and severe oxygen desaturation, as well as reduced need for assisted ventilation with
25 capnography. Two closed claim reviews both found that inadequate oxygenation/ventilation was the
26 most frequent event leading to a claim related to PSA outside the operating room.^{28,29} The potential
27 cost burden is demonstrated by the median cost of a claim settled being USD 330,000 (in 2007 USD).²⁸
28 The authors reported that better monitoring would have reduced the number of claims.²⁸ A similar
29 message was returned following the fourth National Audit Project in the UK, which analyzed major
30 complications of airway management in the National Health Service and determined that
31 capnography monitoring could have led to earlier identification of airway obstruction, potentially
32 preventing 74% of death or neurological injury cases.^{30,31} Studies included in the present meta-analysis
33 reported that disordered ventilation as detected by capnography preceded desaturation events by 30
34 to 60 seconds.³²
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 The meta-analysis did find an increase in bradycardia with capnography monitoring that was non-
50 significant, but consistent among the three included studies reporting the endpoint. However, in each
51 of the three trials, patients in the capnography arm had larger doses and increased use of multiple
52 agents for inducing PSA. Such confounding is plausible, and may not be unusual. In a non-blinded
53 study published after the present analysis, the authors identified increased incidence of hypotension
54
55
56
57
58
59
60

1
2
3 in the capnography arm, in addition to higher sedative doses, patient ASA class, and incidence of
4 comorbidities.³³ All other findings of the current analysis were in line with expectations around the
5 potential benefits of capnography. Earlier identification of respiratory compromise appears to result in
6 more timely intervention and prevention of its escalation into patient harm.
7
8
9
10

11 As with all data synthesis projects, the present study is only as accurate and reliable as the data
12 underlying it. In the literature, there are examples of newly-published clinical trials that do not align
13 with the results of published meta-analyses, and meta-analysis results changing on the publication of
14 new data.^{34,35} The systematic nature of study identification and inclusion criteria in the present analysis
15 was designed to identify all available literature and provide the most robust estimates of intervention
16 effect. However, the included studies came from a variety of hospital settings, in which the rate of
17 patient safety events might vary. Analyses for particular settings were undertaken, but were then
18 limited by reduced data availability. In total, this analysis represented 4,083 patients (control 2,053 and
19 Capnography 2,030) over 11 studies. Between trials, the number of patients enrolled varied between
20 132 and 757. Notably, only the four studies including >500 patients identified rare outcomes, such as
21 differences in use of assisted ventilation.
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **CONCLUSIONS**

37
38
39 The results of this comprehensive meta-analysis of high-quality clinical trials provide clear and
40 consistent evidence of decreased respiratory compromise when capnography monitoring is used
41 during procedural sedation and analgesia (PSA). Specifically, the analysis identified a statistically
42 significant and clinically meaningful reduction in apnea, as well as in mild and severe oxygen
43 desaturation. Large, well designed, randomized controlled trials to provide direct links between use of
44 capnography and reduction in patient harm may not be feasible. In turn, calls for this type of primary
45 evidence may delay adoption of capnography monitoring during PSA as a valuable tool for early
46 intervention and improved patient safety.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Word Count** 3,572
4
5
6
7

8
9 **AUTHOR CONTRIBUTIONS**

10
11 MM formulated the research question; RFP and RS devised the search strategy and data extraction
12 protocol, which was critically reviewed and revised by MM, JRL and MMRFS; RFP and RS then
13 conducted the literature searches, screening, data extraction, and meta-analysis, and co-wrote the
14 manuscript; MM, JRL and MMRFS critically reviewed the manuscript and made substantive revisions
15 prior to submission.
16
17
18
19
20
21

22
23 **DATA SHARING STATEMENT**

24
25 All data used to derive the outcomes presented in the study are documented in the manuscript and
26 supplementary materials. No additional data are therefore available.
27
28
29

30
31 **PUBLICATION RIGHTS**

32
33 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of
34 all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to
35 the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and
36 any other BMJPGJ products and sublicences such use and exploit all subsidiary rights, as set out in our
37 licence.
38
39
40
41
42
43
44
45

46
47 **TRANSPARENCY DECLARATION**

48
49 The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and
50 transparent account of the study being reported. No important aspects of the study have been
51 omitted and any discrepancies from the study as planned (and, if relevant, registered) have been
52 explained.
53
54
55
56
57
58
59
60

ETHICAL APPROVAL

No ethical approval was required for the study as all data were derived from published data; neither animal nor human subjects were enrolled as part of the present study.

FUNDING AND STUDY SPONSOR ROLE

This study was funded by Medtronic plc following a research proposal submitted by Ossian Health Economics and Communications GmbH. The sponsor reviewed the final manuscript prior to submission, but submission was not contingent on a particular outcome of the analysis.

FINANCIAL AND COMPETING INTEREST DISCLOSURE

All authors have completed the Unified Competing Interest forms at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare:

- Michael Mestek is a full-time employee of Medtronic plc.
- Richard Pollock is a full-time employee of Ossian Health Economics and Communications GmbH, which received research and consultancy fees from Medtronic plc. to conduct the literature review and meta-analysis and prepare the manuscript.
- Rhodri Saunders was a full-time employee of Ossian Health Economics and Communications GmbH at the time of performing the meta-analysis and is currently a director of Coreva Scientific GmbH & Co. KG.
- Michel MRF Struys's research group/department received grants and funding from The Medicines Company (USA), Masimo (USA), Fresenius (Germany), Acacia Design (The Netherlands), Medtronic (USA) and honoraria from The Medicines Company (USA), Masimo (USA), Fresenius (Germany), Baxter (USA), Medtronic (USA), Demed Medical (Belgium).
- Jenifer R. Lightdale has served as a consultant for Medtronic and Norgine, and has received speaker honorarium from Mead-Johnson and Perrigo.


TABLES AND FIGURES

Table 1 Included studies reporting endpoints of interest

Study (reference)	Country	Trial dates	Modified Jadad	Potential for bias	Hospital setting	Depth of sedation	Sedative	N (control, Cap)
Beitz 2012 ³⁶	Germany	Feb-10, Jan-11	5.5	High: 3	Colonoscopy	"adequate"	Propofol	757 (374, 383)
Deitch 2010 ³⁷	US	Nov-06, Feb-08	5.5	Low: 0	Emergency department	Moderate	Propofol	132 (64, 68)
Friedrich-Rust 2014 ³⁸	Germany	Jun-12, May-13	6	Low: 0	Colonoscopy	Deep	Propofol+	533 (266, 267)
Kochhar 2015 ³⁹	US	NA	3.5	Low: 0	EGD	Moderate	Opioid and BZP	210 (108, 102)
Langhan 2015 ⁴⁰	US	Sep-11, Jan-13	6	Low: 0	Pediatric emergency department	NA	Ketamine, midazolam	154 (77, 77)
Lightdale 2006 ⁶	US	Dec-03, Nov-04	8	Low: 0	Endoscopy	Moderate	Fentanyl, midazolam	163 (80, 83)
Mehta 2014 ⁴¹	US	NA	3.5	Low: 0	Colonoscopy	Moderate	Opioid and BZP	232 (115, 117)
Qadeer 2009 ⁵	US	Jan-07, May-08	7.5	Moderate: 1	ERCP and EUS	NA	Midazolam+	247 (124, 123)
Slagelse 2013 ⁴²	Denmark	Sep-10, Jan-11	6	No: 0	Endoscopy	NA	Propofol	540 (277, 263)
van Loon 2014 ³²	Netherlands	Apr-10, Jan-11	5	No: 0	Gynecology	Deep	Propofol	415 (209, 206)
Zongming 2014 ⁴³	China	Nov-10, May-13	6	No: 0	Abortion	Deep	Propofol	700 (359, 341)


+, in combination with multiple other agents; BZP, benzodiazepine; Cap, Capnography (arm); EGD, Esophagogastroduodenoscopy; ERCP, Endoscopic retrograde cholangiopancreatography; EUS, Endoscopic ultrasonography

Figure 1 Mild and severe desaturation are reduced with capnography monitoring



The odds ratios for the mild desaturation endpoint are presented for high-quality studies (primary analysis) for mild desaturation (A) and severe desaturation (B). CI, Confidence interval; M-H, Mantel-Haenszel

Figure 2 Need for assisted ventilation is consistently reduced with capnography monitoring



The odds ratios for the assisted ventilation endpoint are presented for high quality studies (primary analysis, A), which were also all the studies with data. CI, Confidence interval; M-H, Mantel-Haenszel

Table 2 Sensitivity analyses around the primary analyses, treatment effect is the odds ratio [95% confidence interval]

Scenario	Desaturation, mild	Desaturation, severe	Apnea	Bradycardia	Hypotension	Assisted ventilation	Supplemental oxygen
Base case (high quality studies)	0.54 [0.44, 0.66]	0.49 [0.34, 0.71]	0.49 [0.32, 0.75]	1.23 [0.87, 1.74]	1.03 [0.74, 1.43]	0.54 [0.25, 1.16]	0.83 [0.59, 1.17]
All studies with data	0.65 [0.51, 0.81]	0.47 [0.34, 0.66]	0.75 [0.43, 1.33]	1.23 [0.87, 1.74]	1.03 [0.74, 1.43]	0.54 [0.25, 1.16]	0.93 [0.65, 1.33]
Moderate sedation	0.67 [0.44, 1.04]	–	0.92 [0.52, 1.64]	–	–	–	–
US only	0.64 [0.44, 0.93]	0.35 [0.21, 0.59]	0.75 [0.43, 1.33]	–	–	–	0.82 [0.27, 2.54]
Europe only	0.65 [0.52, 0.81]	0.61 [0.40, 0.93]	–	1.46 [0.70, 3.03]	0.95 [0.64, 1.40]	0.57 [0.25, 1.29]	0.91 [0.63, 1.30]
Studies with potential bias excluded	0.69 [0.58, 0.82]	0.51 [0.28, 0.90]	0.92 [0.52, 1.64]	1.46 [0.69, 3.08]	0.95 [0.64, 1.41]	0.56 [0.25, 1.23]	1.12 [0.81, 1.55]
Studies in pediatrics excluded	0.64 [0.54, 0.75]	0.47 [0.34, 0.66]	0.79 [0.38, 1.65]	1.23 [0.87, 1.74]	1.03 [0.74, 1.43]	0.54 [0.25, 1.16]	0.90 [0.63, 1.31]
Gender-specific studies excluded	0.60 [0.50, 0.72]	0.45 [0.31, 0.63]	0.75 [0.43, 1.33]	1.23 [0.87, 1.74]	1.02 [0.71, 1.48]	0.57 [0.25, 1.29]	0.83 [0.59, 1.17]
Studies with mean age >30 years	0.59 [0.49, 0.70]	0.49 [0.33, 0.74]	0.79 [0.38, 1.65]	1.23 [0.87, 1.74]	1.03 [0.74, 1.43]	0.54 [0.25, 1.16]	0.80 [0.57, 1.14]

CI, confidence interval; OR, odds ratio; US, United States

SUPPLEMENT

METHODS: Literature screening and data extraction

All returned articles were consolidated in a database (Sourcerer, Covalence Research Ltd, London UK), and duplicate studies were removed. Title and abstract screening using criteria detailed in (Supplement, Table 4) was performed independently by RS and RFP. Full-text versions of all non-excluded articles were retrieved by MM and reviewed independently by RS and RFP using the inclusion criteria in Table 4 (Supplement). Data were extracted from all articles included after abstract and full-text review. Extracted data included the number of patients with events and the population at risk, in addition to items required to assess article quality and bias. This was performed independently by RS and RFP and checked by ME and MMS. All extracted endpoint data were reviewed by JL and MMS for clinical utility. The aim was to ensure that all synthesized data relate to clinically equivalent endpoints

RESULTS: Hypotension


Four studies reported the outcome and all were classified as being of high-quality. The incidence of hypotension was equivalent between capnography and control arms in all studies except the one that lacked a definition for the endpoint. Between study heterogeneity was low ($I^2 = 0\%$) and the estimated OR tended to one (OR 1.03, 95% CI 0.71–1.43; Supplement, Figure 7). There is no evidence of capnography monitoring influencing the incidence of this sedation-related adverse event.

RESULTS: Supplemental oxygen

Although not a target endpoint in the protocol, six studies reported the requirement for oxygen supplementation. Of these, five studies were classified as high-quality and the primary analysis returned evidence of heterogeneity ($I^2 = 41$) and an OR of 0.83 (95% CI 0.59–1.17; Supplement, Figure 7). When analyzing all available data, the OR was 0.93 (95% CI 0.65–1.33).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3 **The respiratory compromise cascade**



view only

Table 3 The literature search strategy employed for PubMed was used as a basis for searching other literature databases


Search	Search string	Results returned in PubMed
#1	Capnogra*[tiab] OR ETCO2[tiab] OR (("end-tidal"[tiab] OR monitor*[tiab]) AND ("carbon dioxide"[tiab] or CO2[tiab])) OR sidestream[tiab] OR mainstream[tiab] OR microstream[tiab] OR "Capnography"[Mesh] OR (("Monitoring, Physiologic"[Mesh] OR "Monitoring, Intraoperative"[Mesh] OR "Intraoperative Care"[Mesh]) AND ("carbon dioxide"[tiab] or CO2[tiab]))	20,192
#2	"Conscious Sedation"[Mesh] OR "Deep Sedation"[Mesh] OR "procedural sedation"[tiab] OR "moderate sedation"[tiab] or "conscious sedation"[tiab] or "deep sedation"[tiab] or sedati*[tiab] or anesthes*[tiab]	175,021
#3	"Randomized Controlled Trials as Topic"[Mesh] OR "Randomized Controlled Trial"[Publication Type] OR RCT[tiab] OR ((random*[tiab] OR clinic*[tiab]) AND control*[tiab] AND (trial[tiab] OR study[tiab]))	770,467
#4	#1 AND #2 AND #3	410
#5	#4 AND "1995/01/01"[PDAT] : "2015/12/31"[PDAT]	348

Table 4 Study exclusion and inclusion criteria

Exclusion criteria	Inclusion criteria
Research not in humans [106, 111]	Presents data for sedation (procedural, moderate, or deep) during ambulatory surgery
Not a randomized, controlled trial [172, 163]	Reports at least one of the following outcomes (apnea, aspiration, bradycardia, desaturation/hypoxia, hypotension, mortality)
Does not include capnography as the intervention [559, 566]	Uses time capnography (as opposed to volumetric)
Includes fewer than 40 patients in either arm [5, 2]	Is specific to the hospital setting

Numbers in brackets provide the number of articles assigned that reason for exclusion by each of the two independent reviewers (RS, RFP)

Figure 4 Literature review flow diagram




Full details of exclusion criteria provided by both independent reviewers during abstract screening are given in Table 2.

Table 5 Endpoint definitions within included studies

Study	Desaturation, mild, SpO ₂ %	Desaturation, severe, SpO ₂ %	Apnea	Bradycardia, HR beats/minute	Hypotension, SBP mm Hg	Supplemental oxygen
Beitz 2012	<90	≤85		<50	<90	>2 L/min
Deitch 2010	<93 for ≥15 seconds					
Friedrich-Rust 2014	<90 for ≥15 seconds	<85		<50	<100	>2 L/min
Kochhar 2015	<90 for ≥10 seconds	≤85	No capnogram for ≥5 seconds			
Langhan 2015	<95					
Lightdale 2006	<95					
Mehta 2014	<90 for ≥10 seconds	<85				
Qadeer 2009	<90 for ≥15 seconds	≤85	No capnogram for ≥15 seconds		Not defined	Any use
Slagelse 2013	<92					Any increase
van Loon 2014	<91	<81				Any increase
Zongming 2014	<90	≤85		<50	<90	>3 L/min

HR, Heart rate; SBP, Systolic blood pressure; SpO₂, Oxygen saturation


Figure 5 Mild desaturation is reduced with capnography monitoring



The odds ratios for the mild desaturation endpoint are presented for high-quality studies (primary analysis, A), all studies with data (B) and studies with an endpoint defined as oxygen saturation <90% (C). CI, Confidence interval;


M-H, Mantel-Haenszel

Figure 6 Severe desaturation is reduced with capnography monitoring




The odds ratios for the severe desaturation endpoint are presented for high quality studies (primary analysis, A), all studies with data (B) and studies with an endpoint defined as oxygen saturation <85% (C). CI, Confidence interval; M-H, Mantel-Haenszel

Figure 7 Evidence of reduced apnea incidence with capnography monitoring and a potential trend towards reduced need for supplemental oxygen



The odds ratios for the apnea endpoint are presented for high quality studies (primary analysis, A) and all studies with data (B). Odds ratios for the use of supplemental oxygen are presented for high quality studies (primary analysis, C) and all studies with data (D). CI, Confidence interval; M-H, Mantel-Haenszel

Figure 8 Bradycardia tends to be increased with capnography monitoring, but there is little impact on the incidence of hypotension



The odds ratios for the bradycardia (A) and hypotension (B) endpoints are presented for high quality studies (primary analysis), which were also all the studies with data. CI, Confidence interval; M-H, Mantel-Haenszel

REFERENCES

- ¹ Sharma VK, Nguyen CC, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE. A national study of cardiopulmonary unplanned events after GI endoscopy. *Gastrointest Endosc.* 2007;66:27–34.
- ² Gangi S, Saidi F, Patel K, Johnstone B, Jaeger J, Shine D. Cardiovascular complications after GI endoscopy: occurrence and risks in a large hospital system. *Gastrointest Endosc.* 2004;60:679–85.
- ³ Erden IA, Pamuk AG, Akinci SB, Koseoglu A, Aypar U. Comparison of two ketamine-propofol dosing regimens for sedation during interventional radiology procedures. *Minerva anesthesiologica* 2010;76:260–5.
- ⁴ Lichtenstein DR, Jagannath S, Baron TH, *et al.* Sedation and anesthesia in GI endoscopy. *Gastrointest Endosc.* 2008;68:205–16.
- ⁵ Qadeer MA, Vargo JJ, Dumot JA, *et al.* Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. *Gastroenterology.* 2009;136:1568–76.
- ⁶ Lightdale JR, Goldmann DA, Feldman HA, Newburg AR, DiNardo JA, Fox VL. Microstream capnography improves patient monitoring during moderate sedation: a randomized, controlled trial. *Pediatrics.* 2006;117:e1170–8.
- ⁷ Cotton PB, Eisen GM, Aabakken L, *et al.* A lexicon for endoscopic adverse events: report of an ASGE workshop. *Gastrointest Endosc.* 2010;71:446–54.
- ⁸ Vargo JJ, Cohen LB, Rex DK, Kwo PY. Position statement: nonanesthesiologist administration of propofol for GI endoscopy. *Gastrointest Endosc.* 2009;70:1053–9.
- ⁹ Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk Factors for Hypoxemia During Ambulatory Gastrointestinal Endoscopy in ASA I-II Patients. *Dig Dis Sci.* 2009;54(5):1035–40.

- 1
2
3
4 ¹⁰ Radaelli F, Terruzzi V, Minoli G. Extended/advanced monitoring techniques in gastrointestinal
5
6 endoscopy. *Gastrointest Endosc Clin N Am*. 2004;14:335–52.
7
8
9 ¹¹ Kober A, Schubert B, Bertalanffy P, et al. Capnography in non-tracheally intubated emergency
10
11 patients as an additional tool in pulse oximetry for prehospital monitoring of respiration. *Anesth*
12
13 *Analg*. 2004;98:206–10.
14
15 ¹² Soto RG, Fu ES, Vila H, Jr., Miguel RV. Capnography accurately detects apnea during monitored
16
17 anesthesia care. *Anesth Analg*. 2004;99:379–82.
18
19
20 ¹³ Thomas PE. What's the latest on carbon dioxide monitoring? *Neonatal Netw*. 2004;23:70–2.
21
22
23 ¹⁴ Yildzdas D, Yapcoglu H, Ylmaz HL. The value of capnography during sedation or sedation/analgesia
24
25 in pediatric minor procedures. *Pediatr Emerg Care*. 2004;20:162–5.
26
27
28 ¹⁵ American Society for Gastrointestinal Endoscopy, American College of Gastroenterology,
29
30 Association TAG. Universal adoption of capnography for moderate sedation in adults undergoing
31
32 upper endoscopy and colonoscopy has not been shown to improve patient safety or clinical outcomes
33
34 and significantly increases costs for moderate sedation. Available from:
35
36 <http://www.asge.org/assets/0/71542/71544/90dc9b63-593d-48a9-bec1-9f0ab3ce946a.pdf> Last
37
38 accessed April 11, 2016.
39
40
41 ¹⁶ Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respiratory events during
42
43 procedural sedation: a meta-analysis. *J Clin Anesth*. 2011;23:189–96.
44
45
46 ¹⁷ Cook TM. The winds of change - progress in the implementation of universal capnography.
47
48 *Anaesthesia*. 2016;71(4):363–8.
49
50
51 ¹⁸ Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is
52
53 blinding necessary? *Control Clin Trials*. 1996;17(1):1–12.
54
55
56 ¹⁹ Review Manager. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark.
57
58
59
60

- 1
2
3
4²⁰ DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–88.
5
6
7²¹ Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of
8
9 disease. *Journal of the National Cancer Institute* 1959;22:719–48.
10
11²² Guimaraes ES, Campbell EJ, Richter JM. The Safety of Nurse-Administered Procedural Sedation
12
13 Compared to Anesthesia Care in a Historical Cohort of Advanced Endoscopy Patients. *Anesth Analg*.
14
15 2014;119(2):349–56.
16
17²³ Zhong B. How to Calculate Sample Size in Randomized Controlled Trial? *J Thorac Dis*. 2009;1(1):51–
18
19 54.
20
21
22
23²⁴ Saunders R, Erslon M, Vargo J. Modeling the costs and benefits of capnography monitoring during
24
25 procedural sedation for gastrointestinal endoscopy. *Endosc Int Open*. 2016;4(3):E340–51.
26
27
28²⁵ Klare Peter, Reiter Johanna, Meining Alexander, et al. Capnographic monitoring of midazolam and
29
30 propofol sedation during ERCP: a randomized controlled study (EndoBreath Study). *Endoscopy*.
31
32 2016;48:42–50.
33
34
35²⁶ Ehrenfeld JM, Funk LM, Van Schalkwyk J, Merry AF, Sandberg WS, Gawande A. The incidence of
36
37 hypoxemia during surgery: evidence from two institutions. *Can J Anaesth*. 2010;57(10):888–97.
38
39
40²⁷ Dunham CM, Hileman BM, Hutchinson AE, Chance EA, Huang GS. Perioperative hypoxemia is
41
42 common with horizontal positioning during general anesthesia and is associated with major adverse
43
44 outcomes: a retrospective study of consecutive patients. *BMC Anesthesiol*. 2014;14:43.
45
46
47²⁸ Metzner J, Posner KL, Domino KB. The risk and safety of anesthesia at remote locations: the US
48
49 closed claims analysis. *Curr Opin Anaesthesiol*. 2009;22(4):502–8.
50
51
52²⁹ Robbertze R, Posner KL, Domino KB. Closed claims review of anesthesia for procedures outside the
53
54 operating room. *Curr Opin Anaesthesiol*. 2006;19(4):436–42.
55
56
57
58
59
60

1
2
3
4 ³⁰ Cook TM, Woodall N, Harper J, Bengner J. Major complications of airway management in the UK:
5
6 results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult
7
8 Airway Society. Part 2: intensive care and emergency departments. *Br J Anaesth*. 2011;106:632–42.
9

10
11 ³¹ Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway
12
13 management in the UK: results of the Fourth National Audit Project of the Royal College of
14
15 Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. *Br J Anaesth*. 2011;106(5):632–42.
16

17
18 ³² van Loon K, van Rheineck Leyssius AT, van Zaane B, Denteneer M, Kalkman CJ. Capnography during
19
20 deep sedation with propofol by nonanesthesiologists: a randomized controlled trial. *Anesth Analg*.
21
22 2014;119:49–55.
23

24
25 ³³ Campbell SG, Magee KD, Zed PJ, *et al*. End-tidal capnometry during emergency department
26
27 procedural sedation and analgesia: a randomized, controlled study. *World J Emerg Med*.
28
29 2016;7(1):13–8.
30

31
32 ³⁴ LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses
33
34 and subsequent large randomized, controlled trials. *N Engl J Med*. 1997;337(8):536–42.
35

36
37 ³⁵ Trikalinos TA, Churchill R, Ferri M, *et al*. Effect sizes in cumulative meta-analyses of mental health
38
39 randomized trials evolved over time. *J Clin Epidemiol*. 2004;57(11):1124–30.
40

41
42 ³⁶ Beitz A, Riphaut A, Meining A, *et al*. Capnographic monitoring reduces the incidence of arterial
43
44 oxygen desaturation and hypoxemia during propofol sedation for colonoscopy: a randomized,
45
46 controlled study (ColoCap Study). *Am J Gastroenterol*. 2012;107:1205–12.
47

48
49 ³⁷ Deitch K, Miner J, Chudnofsky CR, Dominici P, Latta D. Does end tidal CO2 monitoring during
50
51 emergency department procedural sedation and analgesia with propofol decrease the incidence of
52
53 hypoxic events? A randomized, controlled trial. *Ann Emerg Med*. 2010;55:258–64.
54

55
56 ³⁸ Friedrich-Rust M, Welte M, Welte C, *et al*. Capnographic monitoring of propofol-based sedation
57
58 during colonoscopy. *Endoscopy*. 2014;46:236–44.
59
60

1
2
3
4 ³⁹ Kochhar G, Mehta PP, Kirsh B, Rizk MK, Wang Y, John B, Albeldawi M, Vargo JJ. Tu2057 Does
5
6 Capnography Prevent Hypoxemia in ASA 1-2 Outpatients Undergoing Elective EGD Targeting
7
8 Moderate Sedation? Results from a Prospective, Randomized, Single Blinded Study.
9
10 Gastroenterology;148:S-1196.
11

12
13 ⁴⁰ Langan ML, Shabanova V, Li FY, Bernstein SL, Shapiro ED. A randomized controlled trial of
14
15 capnography during sedation in a pediatric emergency setting. Am J Emerg Med. 2015;33:25-30.
16

17
18 ⁴¹ Mehta P, Kochhar G, Albeldawi M, *et al.* Capnographic Monitoring Does Not Improve Detection of
19
20 Hypoxemia in Colonoscopy With Moderate Sedation: A Randomized, Controlled Trial. Am J
21
22 Gastroenterol. 2014;109:S588.
23

24
25 ⁴² Slagelse C, Vilmann P, Hornslet P, Jorgensen HL, Horsted TI. The role of capnography in endoscopy
26
27 patients undergoing nurse-administered propofol sedation: a randomized study. Scand J
28
29 Gastroenterol. 2013;48(10):1222-30.
30

31
32 ⁴³ Zongming J, Zhonghua C, Xiangming F. Sidestream capnographic monitoring reduces the incidence
33
34 of arterial oxygen desaturation during propofol ambulatory anesthesia for surgical abortion. Med Sci
35
36 Monit. 2014;20:2336-42.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013402.R1
Article Type:	Research
Date Submitted by the Author:	19-Oct-2016
Complete List of Authors:	Saunders, Rhodri; Coreva Scientific GmbH & Co. KG. Struys, Michel; University of Groningen, Department of Anesthesiology Pollock, Richard; Ossian Health Economics and Communications GmbH, Mestek, Michael; Medtronic Inc, Patient Monitoring & Recovery Lightdale, Jenifer; UMass Memorial Children's Medical Center, Pediatric Gastroenterology
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Respiratory medicine
Keywords:	Capnography, Meta-analysis, Procedural sedation, Ambulatory surgery

SCHOLARONE™
Manuscripts

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY**MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Authors: Rhodri Saunders DPhil^{1,2}, Michel MRF Struys MD PhD FRCA (Hon)³,
Richard F Pollock MA MSci², Michael Mestek PhD⁴, Lightdale JR MD MPH⁵

Affiliations: ¹ Coreva Scientific GmbH & Co. KG., Freiburg, Germany
² Ossian Health Economics and Communications, Basel, Switzerland
³ Department of Anesthesiology, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands; Department of
Anesthesia, Ghent University, Gent, Belgium
⁴ Medtronic, Patient Monitoring & Recovery, Boulder, CO
⁵ Pediatric Gastroenterology, UMass Memorial Children's Medical Center,
Worcester, MA; University of Massachusetts Medical School, Worcester,
MA

Corresponding author: Richard Pollock MA MSci
Ossian Health Economics and Communications GmbH,
Bäumleingasse 20,
4051 Basel, Switzerland
+41 61 271 62 14
pollock@ossianconsulting.com

Word count: 5,140

Running title: Patient safety during sedation: a meta-analysis

Key words: Capnography; Respiratory compromise; Oxygen desaturation; Apnea;
Assisted ventilation;

Target journal: BMJ

Grant support: This study was supported by funding from Medtronic plc.

ABSTRACT

Objective

To evaluate the effect of capnography monitoring on sedation-related adverse events during procedural sedation and analgesia (PSA) administered during ambulatory surgery relative to visual assessment and pulse oximetry alone.

Design and Setting

Systematic literature review and random effects meta-analysis of randomized controlled trials (RCTs) reporting sedation-related adverse event incidence when adding capnography to visual assessment and pulse oximetry in patients undergoing PSA during ambulatory surgery in the hospital setting. Searches for eligible studies published between 1995 and 2015 (inclusive) were conducted in PubMed, the Cochrane Library and EMBASE without any language constraints. Searches were conducted in June, 2015, screening and data extraction was conducted by two independent reviewers, and study quality was assessed using a modified Jadad scale.

Interventions

Capnography monitoring relative to visual assessment and pulse oximetry alone.

Primary and Secondary Outcome Measures

Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint), apnea, aspiration, bradycardia, hypotension, premature procedure termination, respiratory failure, use of assisted/bag-mask ventilation and death during PSA.

Results

The literature search identified 861 unique articles, of which 11 were ultimately included in the meta-analysis. Addition of capnography to visual assessment and pulse oximetry was associated with a significant reduction in the odds of apnea (OR 0.49, 95% CI 0.32–0.75), as well as mild (OR 0.54, 95% CI

1
2
3 0.44–0.66) and severe (OR 0.49, 95% CI 0.34–0.71) desaturation. Reduced occurrence of assisted
4
5 ventilation was also observed with capnography, but this did not reach significance.
6
7

8 **Conclusions**

9
10 Meta-analysis of 11 RCTs published between 2006 and 2015 showed a reduction in respiratory
11
12 compromise (from respiratory insufficiency to failure) during PSA with the inclusion of capnography
13
14 monitoring. In particular, use of capnography was associated with less mild and severe oxygen
15
16 desaturation, and may help to avoid the need for assisted ventilation.
17
18
19

20 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

21 **Strengths**

- 22
23
24
25 • The studies included in the analysis were all published in 2006 or later, representing modern
26
27 medical practice and providing consistent evidence of improvements in patient safety with the use
28
29 of capnography monitoring.
30
31
- 32
33 • The study findings further substantiate a previously-published meta-analysis, which found that
34
35 capnography monitoring was more likely to detect adverse events.
36

37 **Limitations**

- 38
39
40 • The level of sedation employed in each study was not uniformly reported, resulting in a mixture of
41
42 different sedation levels in the primary analysis and precluding an analysis of outcomes by
43
44 sedation level.
45
- 46
47 • As with all meta-analyses, the study findings may be affected by publication, search or selection
48
49 bias affecting the studies ultimately included in the analysis; however, where possible, steps were
50
51 taken to minimize the effects of bias on the analysis, but the degree to which these steps were
52
53 successful is difficult to quantify.
54
55
56
57
58
59
60

BACKGROUND AND AIMS

The administration of procedural sedation and analgesia (PSA) involves achieving a drug-induced depression in level of consciousness and pain to ensure the comfort and cooperation of patients undergoing non-surgical and minor surgical procedures. Significant adverse events associated with PSA are relatively rare but not inconsequential, and can include severe oxygen desaturation, bradycardia, hypotension, and cardiac arrest.^{1,2} Consensus dictates that levels of sedation are directly related to patient risk during PSA, as is the potential for unintended progression from moderate to deep sedation.³ Generally speaking, most cardiopulmonary events associated with PSA stem from poor or absent ventilation cascading into hypoxia, tissue injury and cardiac decompensation (Supplement, Figure 3). In turn, maintaining patient safety involves the identification of respiratory compromise to prompt the use of clinical intervention before further complications occur.^{4,5,6,7,8,9}

In current clinical practice, patient monitoring during PSA often relies on visual assessment of ventilation and use of pulse oximetry, which reflects hypoxemia.^{10,11,12,13,14} To date, a mandate to include capnography in patient monitoring, as a means of early detection of alveolar hypoventilation, has remained a topic of debate.¹⁵ In particular, there has been a perceived gap between various study outcomes and evidence of improved patient safety. No studies have provided “hard proof” that addition of capnography to patient monitoring may reduce severe morbidity and mortality during PSA (in part because of ethical considerations to ensure patient rescue), and efforts to use meta-analysis to determine the utility of capnography to identify clinically significant respiratory depression have been faulted for large heterogeneity and non-standard endpoints.^{16,17}

The primary aim of the present systematic review and meta-analysis was to understand whether capnography added to patient monitoring only (consisting of pulse oximetry and visual inspection of ventilation) reduces the incidence (or odds) of adverse events during PSA based on randomized controlled trials of patients undergoing a variety of surgical procedures. As a secondary aim, a power calculation was performed to determine the number of patients that would be required to

1
2
3 demonstrate a reduction in patient harm, defined as severe morbidity or mortality, in a prospective
4
5 clinical trial of capnography versus visual assessment with pulse oximetry. The analysis was based on
6
7 the hypothesis that earlier and more sensitive detection of ventilatory changes with capnography may
8
9 allow for more timely intervention and prevention of potential adverse events, such as cardiac
10
11 dysrhythmias. Throughout the analyses, we sought to provide the highest level of synthesized
12
13 evidence with respect to the clinical utility of capnography monitoring during PSA. To mitigate
14
15 potential pitfalls due to non-standard endpoints, particular emphasis was placed on maintaining a
16
17 consistent definition of adverse events across all studies included.
18
19

20 21 **METHODS**

22
23
24 Literature searches were conducted in PubMed, the Cochrane Library and EMBASE. Search terms were
25
26 a combination of Medical Subject Heading (MeSH) terms and free-text searches within the articles title
27
28 and abstract. Searches aimed to identify all literature reporting on randomized, controlled trials in
29
30 patients receiving sedation during ambulatory surgery and in which visual assessment of ventilation
31
32 and pulse oximetry monitoring (control) was compared with control plus capnography. No "grey" or
33
34 unpublished literature was included in the search strategy and, as the review protocol was not
35
36 registered in advance, the full search strategy (Supplement, Table 3) and additional details are
37
38 provided in the Supplement. Only articles or abstracts published on or after January 1, 1995 were
39
40 included and all searches were performed on June 17, 2015. No language exclusion was applied and
41
42 inclusion was not dependent on the capnography monitor in use. After duplicate removal, title and
43
44 abstract screening (Supplement, Table 4) was performed independently by RS and RFP. Full-text
45
46 versions of all non-excluded articles were retrieved by MM and reviewed independently by RS and
47
48 RFP. Data were then extracted independently by RS and RFP into data extraction forms in Microsoft
49
50 Excel (Microsoft Corporation, Redmond, WA). Any discrepancies in the extracted data were resolved
51
52 by reference to the original study, reaching consensus between RS and RFP. All extracted endpoint
53
54 data were reviewed by JL and MMS for clinical utility to ensure that all synthesized data relate to
55
56
57
58
59
60

1
2
3 clinically equivalent endpoints. Extracted data included the number of patients with events and the
4
5 population at risk, in addition to items required to assess article quality and bias. Reference lists of
6
7 included studies were not searched.
8
9

10 **Endpoints**

11
12 Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint, with severe
13
14 desaturation defined as $SpO_2 \leq 85\%$), apnea, aspiration, bradycardia, hypotension, premature
15
16 procedure termination, respiratory failure, use of assisted/bag-mask ventilation and death during PSA.
17
18 The protocol was left open for the analysis of other patient safety endpoints that were reported by ≥ 3
19
20 studies. Cardiac arrest and death were considered to be representative of severe morbidity and
21
22 mortality. Notably, the present analysis examined individual endpoints as opposed to composite
23
24 endpoints (e.g. desaturation, apnea, or respiratory depression) and included analyses of more specific
25
26 endpoints, such as oxygen desaturation $<90\%$ and $<85\%$, were also conducted.
27
28
29

30 **Quality and potential bias**

31
32 Assessment of article quality was conducted on a study (as opposed to outcome) level using a
33
34 modified Jadad score,¹⁸ with additional criteria added to make the adaptation specific to monitoring.
35
36 The Jadad score assesses studies based on their design (randomized and blinded) and their reporting
37
38 (all patients accounted for), with a maximal score of 5 (high quality) and a low score of 0 (low quality).
39
40 Additional data included here were endpoint definitions, patient population, hospital location at which
41
42 patients underwent sedation, and the staff responsible for monitoring. In line with the Jadad score,
43
44 items related to trial design could score up to twice as highly as items relating to trial reporting. The
45
46 reporting of the inclusion/exclusion criteria and endpoint definitions scored one point each, and
47
48 reporting the location of sedation, and the monitoring staff scored half-point point each, making the
49
50 maximal score 8 (high quality). For the purposes of analyzing study quality, studies with scores of 0–5
51
52 were considered to be low quality, while studies scoring 5.5–8 were designated as high quality studies.
53
54
55
56
57
58
59
60

1
2
3 Risk of bias in results was evaluated independently from the quality assessment through the
4
5 declaration of funding sources and conflicts of interest. If the study was funded by industry then the
6
7 study scored 2, any conflicts of interest declared relating to industry funding outside of the current
8
9 research publication scored 1. A study with low potential for bias, therefore, would have a score of 0. A
10
11 high potential for bias was defined as a score of 3, while a score of 1–2 was considered to indicate
12
13 moderate potential for bias. The absence of industry funding was not taken to signify an absence of
14
15 bias, but the presence of industry funding or conflicts of interest was assumed to be an indicator of
16
17 bias.¹⁹

20 Analysis

21
22 Data extraction, initial data consolidation and summary statistics were performed in Microsoft Excel.
23
24 Data for each endpoint were subsequently entered into Review Manager 5.3.4 for results synthesis.²⁰
25
26 Heterogeneity of data was evaluated using Chi^2 and I^2 statistics presented by Review Manager 5.3.4,
27
28 with I^2 further categorized by the tentative Higgins *et al.* heterogeneity categories of: low, moderate
29
30 and high.²¹ The meta-analysis performed calculated the mean intervention effect across all eligible
31
32 studies using (after analysis of heterogeneity) a random effects model as described by DerSimonian
33
34 and Laird.²² An estimate of between-study variation was provided by the Mantel-Haenszel
35
36 methodology.²³ The outcome reported for each endpoint is the pooled mean odds ratio (OR) and its
37
38 95% confidence interval.

39
40
41 Sensitivity analyses were specified *a priori* and the tested conditions were: (1) inclusion of only
42
43 moderate sedation, (2) inclusion of only studies with low risk of bias, (3) inclusion of only studies
44
45 based in the US, (4) inclusion of only studies based in Europe, (5) exclusion of pediatric data, (6)
46
47 exclusion of gender-specific studies, (7) exclusion of data in patients <30 years of age. No formal
48
49 statistical comparisons were made between sensitivity analyses, and intervention effects were not
50
51 calculated for the excluded studies, thereby mitigating the introduction of type 1 error into the
52
53 analysis.
54
55
56
57
58
59
60

Patient involvement

No patients, service users, carers or lay people were involved in the design or conduct of this study.

Outcome measures were all related to patient safety during PSA, but were not developed based on an explicit elicitation of patient priorities, experience, and preferences.

RESULTS

Literature searches of PubMed, the Cochrane Library and EMBASE returned 353, 76, and 672 articles, respectively. After removal of 240 duplicates (55 Cochrane, 185 EMBASE), 861 articles remained for abstract screening. Although reasons for exclusion varied (Supplement, Table 4), the two independent reviewers agreed upon a total of 19 articles to be retained for full-text review (Cohen's kappa, 1.0). Eight articles were excluded on full-text review (Supplement, Figure 4) because they: reported duplicate data (n=3), did not report patient safety data (n=3), and did not include sedation (n=2). The 11 articles included for analysis are presented in Table 1. All studies reported desaturation endpoints, although the definition did vary by study (Supplement, Table 5). Other endpoints were heterogeneously reported, but were in most cases reported by ≥ 3 studies making meta-analysis feasible as per the pre-defined protocol. Results reported are from random-effects models unless otherwise stated. Results for hypotension and use of supplemental oxygen are provided in the Supplement.

Mild desaturation

All studies (Table 1) reported mild desaturation, with the definition varying from an oxygen saturation (SpO_2) of <95% to <90% for ≥ 15 seconds.^{5,6,24,25,26,27,28,29,30,31,32} There was little evidence of heterogeneity ($I^2 = 11\%$, low) in the primary analysis of high quality studies (n=8). Results indicated that capnography significantly reduced the odds of mild desaturation (OR = 0.54, 95% CI 0.44–0.66; Figure 1B); the odds of a mild desaturation event were approximately halved when capnography monitoring is used, compared with no use of capnography. If all available data were included (Supplement, Figure 5B), there was evidence of significant heterogeneity ($I^2 = 49\%$, moderate) with an

1
2
3 OR of 0.65 (95% CI 0.51–0.81). Using exclusively studies with equivalent definitions of mild
4
5 desaturation (<90%, n=6), evidence of heterogeneity ($I^2 = 47%$, moderate) was still present. The OR
6
7 estimated from these studies was 0.60 (95% CI 0.46–0.77).
8
9

10 **Severe desaturation**

11
12 Six studies, of which three were classified as high quality, reported severe desaturation.^{5,25,26,27,28,29} All
13
14 but one of the studies defined severe desaturation as $SpO_2 </\leq 85%$. The primary analysis for this
15
16 endpoint yielded an OR of 0.49 (95% CI 0.34–0.71), further supporting the significant reduction in the
17
18 odds of desaturation with the inclusion of capnography (Figure 1). As with mild desaturation, there
19
20 was no evidence of heterogeneity in the three high-quality studies ($I^2 = 0%$, low).
21
22

23
24 Synthesizing estimates from all available data supported the primary analysis (Supplement, Figure 6),
25
26 the OR was reduced by 0.02 and the confidence interval tightened (OR 0.47, 95% CI 0.34–0.66). There
27
28 was no significant heterogeneity between studies ($I^2 = 16%$, low). Focusing on the five studies
29
30 reporting an endpoint of $SpO_2 </\leq 85%$, there was no heterogeneity and the OR was estimated at
31
32 0.44 (95% CI 0.32–0.60). Overall, results support a greater than 50% reduction in the odds of severe
33
34 desaturation events if capnography monitoring is used.
35
36

37 **Apnea**

38
39 Apnea was less widely reported or reported in combination with disordered respiration. Comparable
40
41 endpoints were reported by four studies, of which two were high quality.^{5,6,28,30} Primary analysis
42
43 demonstrated a significant reduction in apnea with capnography monitoring (OR 0.49, 95% CI 0.32–
44
45 0.75), with no evidence of heterogeneity (Supplement, Figure 7A). If all studies were included the
46
47 degree of heterogeneity became significant ($I^2 = 75%$, high) and the outcome lacked significance at
48
49 the 5% level (OR 0.75, 95% CI 0.43–1.33; Supplement Figure 7B). The difference between the primary
50
51 and secondary analyses for apnea was driven by the Kochhar *et al.* study, which found apnea to be
52
53 increased in the capnography arm.
54
55
56

57 **Bradycardia**

1
2
3 Three studies, all of high-quality, reported bradycardia outcomes.^{26,27,29} Its definition (heart rate <50
4 beats/minute) was consistent among trials and there was no evidence of between study heterogeneity
5 ($I^2 = 0\%$, low). In all studies, the incidence of bradycardia was higher in the capnography arm
6 compared with the control arm (Supplement, Figure 8). Overall, capnography monitoring was
7 associated with a non-significant increase in bradycardia (OR 1.23, 95% CI 0.87–1.74).
8
9
10
11
12

13 **Assisted ventilation**

14
15
16 Only one study reported one instance of what was termed “respiratory failure,” that was treated with
17 assisted bag-mask ventilation.²⁶ In contrast, the number of studies reporting assisted and/or bag-
18 mask ventilation was sufficient to perform a meta-analysis of this endpoint as a surrogate for
19 respiratory failure. In total, five studies reported this and all were classified as high-quality.^{5,26,27,31,32}
20
21 The primary analysis showed no evidence of heterogeneity and an OR of 0.83 (95% CI 0.59–1.17;
22 Supplement Figure 7C). In every case, the need to provide assisted ventilation was lower in the
23 capnography arm compared with the control arm (Figure 2). The lack of significance reflects the low
24 number of observed events and the resulting lack of power. For this reason, a Peto fixed-effects model
25 was used to estimate the Peto OR, which was 0.54 (95% CI, 0.26–1.12).
26
27
28
29
30
31
32
33
34
35

36 **Sensitivity analyses**

37
38
39 A series of sensitivity analyses were conducted in which the studies included in the estimation of the
40 OR were varied. The results of these analyses are presented in Table 2 and show that results were
41 generally robust to the studies included for data synthesis. There were limited data available to assess
42 the impact of capnography monitoring during moderate sedation. Data available indicate that the
43 impact of capnography is reduced relative to deep sedation. With respect to severe desaturation
44 events, there was also a substantial difference between US and European data. In Europe, addition of
45 capnography monitoring was estimated to reduce the odds of severe desaturation by about 40%; for
46 the US based studies this increased to 65%.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

The findings of a meta-analysis of recent RCTs comparing visual assessment of ventilation and pulse oximetry monitoring with and without capnography during PSA showed that the odds of apnea and oxygen desaturation events were significantly reduced with the use of capnography. Other endpoints that could be affected by capnography monitoring were also considered and the majority was found to be associated with substantial, but not significant, benefits to patient safety. Specifically, and of potential clinical importance, was the consistency of data across multiple high-quality clinical trials reporting a reduced incidence of assisted ventilation with capnography monitoring. No endpoints assessed in the meta-analysis indicated significant patient safety concerns with capnography.

Physician concerns for patient safety often focus on mortality and severe morbidity. There was no evidence that these outcomes differed between control and capnography arms in the present meta-analysis. The incidence of these events during nurse-administered PSA has been reported to be 1 event per 303 procedures (0.33%).³³ Taking this value and using the assumption that capnography could prevent 50% of events, the formula provided by Zhong (2009) to calculate the trial size required to demonstrate statistical superiority returned 27,726 patients.³⁴ Switching to an assumption that capnography would prevent 10% of events, the required trial size was calculated to be >900,000 patients. Not only is the feasibility of performing such a superiority trial low, but meta-analyses such as the present study, are not able to detect this difference from the relatively small number of existing lower-powered studies currently available in peer-reviewed medical literature.

The analysis is timely given the ongoing lively debate as to whether the addition of capnography to patient monitoring during PSA adds value.¹⁷ Without doubt, potential technical and financial burdens have further limited adoption of capnography monitoring in various clinical settings.^{15,17} Nevertheless, it is important to recognize that patient safety benefits may offset a number of these concerns if the outcomes are applicable to current medical practice.³⁵ In this regard, the 11 trials identified in the present analysis were all relatively recent, with the first published study identified in 2006. The data

1
2
3 used in the meta-analysis therefore represents modern medical practice, and provides consistent
4
5 evidence of improvements in patient safety with the use of capnography monitoring.
6

7
8 These findings further substantiate a previously published meta-analysis (Waugh *et al.*), which found
9
10 that capnography monitoring was more likely to detect adverse events, but was faulted for large
11
12 endpoint heterogeneity.¹⁶ In the present meta-analysis, we focused on identifying high-quality studies,
13
14 and on maintaining consistent definitions across all included studies, thereby minimizing potential for
15
16 heterogeneity. The results show that the addition of capnography to patient monitoring during PSA
17
18 results in increased patient safety, with significant reductions in apnea, as well as mild and severe
19
20 levels of oxygen desaturation.
21

22
23 More recently, a meta-analysis by Conway *et al.* reported a significant benefit with capnography
24
25 during colonoscopy only with respect to hypoxemia. However, the study identified and screened only
26
27 a fraction of the literature included in the present analysis (388 papers in Conway *et al.*, compared with
28
29 861 papers in the current study) and retrieved fewer randomized controlled trials (6 versus 11). In
30
31 addition, Conway *et al.* excluded two trials in which an independent observer monitored capnography
32
33 output for all patients, and signaled to the attending physician when respiratory compromise was
34
35 identified with capnography either immediately (intervention) or after a specified delay (control).^{5,6} The
36
37 rationale for this was to prevent unnecessary patient harm while avoiding investigator bias. Based on
38
39 our understanding, the two trials excluded in the Conway *et al.* analysis are the only studies in the
40
41 literature that could be considered fully blinded. Among the other studies, the attending physician
42
43 would have been aware of study arm assignment.^{25,27,32}
44
45

46
47 As with other major assessment tools such as Delphi, Consort, and the Cochrane risk of bias tool,
48
49 blinding is an integral part of the Jadad score used in the present analysis.^{18,36} The trials excluded from
50
51 the Conway *et al.* analysis are both considered to be "high quality" in the present analysis, driven in
52
53 part by the inclusion of blinding in the scoring methodology. Other included trials, though potentially
54
55 more representative of current clinical practice, are open to operator bias, the consequences of which
56
57 were demonstrated in 2012 by Veerus *et al.*³⁷
58
59
60

1
2
3 One potential limitation of the present quality appraisal approach was the lack of validation of the
4
5 modifications to the Jadad score; however, as may be expected, the modified score does significantly
6
7 correlate with the raw Jadad score (adjusted $R^2 = 0.83$, $p < 0.01$). Furthermore, analysis of mild
8
9 desaturation data using a mixed model that took the modified Jadad score as a covariate, found that
10
11 the modified Jadad score accounted for 97.5% of the heterogeneity and had both an intercept
12
13 ($p < 0.05$) and gradient ($p < 0.01$) significantly different from zero. When blinding was removed from
14
15 the score, the model accounted for only 49.9% of heterogeneity and did not reach significance.
16
17 Although there is a clear distinction between real-world practice and a clinical trial, these *post-hoc*
18
19 analyses demonstrate the potential importance of blinding in trial design. Given the exclusion of
20
21 blinded trials, the results of the Conway analysis should be interpreted with this in mind. Nevertheless,
22
23 the finding of consistent outcomes for hypoxemia in Conway *et al.* (relative risk 0.59, 95% CI 0.48 to
24
25 0.73) and mild desaturation in the present analysis (OR 0.54, 95% CI 0.44 to 0.66; RR 0.65, 95% CI 0.57
26
27 to 0.74) was encouraging. These findings are also aligned with a European randomized, controlled trial
28
29 of capnography that was published after the analysis was complete.³⁸

30
31
32
33 Another ongoing debate in PSA concerns the clinical importance of seemingly minor endpoints, such
34
35 as mild desaturation (oxygenation $< 90\%$ for 15 seconds). Although such endpoints have traditionally
36
37 been considered transient and perhaps clinically insignificant during PSA, several recent studies of
38
39 common intraoperative events have suggested that mild desaturation may have more impact on
40
41 post-surgical outcomes than has previously been recognized.³⁹ For example, Dunham *et al.* looked
42
43 retrospectively and determined that surgical patients who experienced perioperative
44
45 hypoxemia/desaturation had a significant increase in their length of hospital stay (+2.0 days,
46
47 $p < 0.0001$).⁴⁰ In turn, the impact of transient desaturation during PSA in terms of patient outcomes and
48
49 quality of life may yet be of importance but remains to be determined.
50
51

52
53 Over all of the studies included in the analysis, there were no reports of patient mortality. Only the
54
55 largest trials reported any requirement for assisted/bag-mask ventilation, which is used as an
56
57 intervention and thereby a proxy measure for potentially life-threatening events. Although it is
58
59
60

1
2
3 generally accepted that much larger studies would be useful to assess whether or not capnography
4
5 monitoring impacts patient major morbidity and mortality, there has been no determination of the
6
7 trial size that would be required. Power calculations suggest such a large randomized controlled trial is
8
9 likely to be impractical.

10
11 For healthcare providers, the most significant finding may be the consistency of data surrounding
12
13 apnea and severe oxygen desaturation, as well as reduced need for assisted ventilation with
14
15 capnography. Two closed claim reviews both found that inadequate oxygenation/ventilation was the
16
17 most frequent event leading to a claim related to PSA outside the operating room.^{41,42} The potential
18
19 cost burden is demonstrated by the median cost of a claim settled being USD 330,000 (in 2007 USD).⁴¹
20
21 The authors reported that better monitoring would have reduced the number of claims.⁴¹ A similar
22
23 message was returned following the fourth National Audit Project in the UK, which analyzed major
24
25 complications of airway management in the National Health Service and determined that
26
27 capnography monitoring could have led to earlier identification of airway obstruction, potentially
28
29 preventing 74% of death or neurological injury cases.^{43,44} Studies included in the present meta-analysis
30
31 reported that disordered ventilation as detected by capnography preceded desaturation events by 30
32
33 to 60 seconds.

34
35 The meta-analysis did find an increase in bradycardia with capnography monitoring that was non-
36
37 significant, but consistent among the three included studies reporting the endpoint. However, in each
38
39 of the three trials, patients in the capnography arm had larger doses and increased use of multiple
40
41 agents for inducing PSA. Such confounding is plausible, and may not be unusual. In a non-blinded
42
43 study published after the present analysis, the authors identified increased incidence of hypotension
44
45 in the capnography arm, in addition to higher sedative doses, patient ASA class, and incidence of
46
47 comorbidities.⁴⁵ All other findings of the current analysis were in line with expectations around the
48
49 potential benefits of capnography. Earlier identification of respiratory compromise appears to result in
50
51 more timely intervention and prevention of its escalation into patient harm.
52
53
54
55
56
57
58
59
60

1
2
3 As with all data synthesis projects, the present study is only as accurate and reliable as the data
4
5 underlying it. In the literature, there are examples of newly-published clinical trials that do not align
6
7 with the results of published meta-analyses, and meta-analysis results changing on the publication of
8
9 new data.^{46,47} The systematic nature of study identification and inclusion criteria in the present analysis
10
11 was designed to identify all available literature and provide the most robust estimates of intervention
12
13 effect. However, the included studies came from a variety of hospital settings, in which the rate of
14
15 patient safety events might vary. Analyses for particular settings were undertaken, but were then
16
17 limited by reduced data availability. In total, this analysis represented 4,083 patients (control 2,053 and
18
19 Capnography 2,030) over 11 studies. Between trials, the number of patients enrolled varied between
20
21 132 and 757. Notably, only the four studies including >500 patients identified rare outcomes, such as
22
23 differences in use of assisted ventilation.
24
25

26 27 **CONCLUSIONS**

28
29 The results of this comprehensive meta-analysis of high-quality clinical trials provide clear and
30
31 consistent evidence of decreased respiratory compromise when capnography monitoring is used
32
33 during procedural sedation and analgesia (PSA). Specifically, the analysis identified a statistically
34
35 significant and clinically meaningful reduction in apnea, as well as in mild and severe oxygen
36
37 desaturation. Large, well designed, randomized controlled trials to provide direct links between use of
38
39 capnography and reduction in patient harm may not be feasible. In turn, calls for this type of primary
40
41 evidence may delay adoption of capnography monitoring during PSA as a valuable tool for early
42
43 intervention and improved patient safety.
44
45
46
47
48
49

50
51 **Word Count** 5,140
52
53
54
55
56
57
58
59
60

AUTHOR CONTRIBUTIONS

MM formulated the research question; RFP and RS devised the search strategy and data extraction protocol, which was critically reviewed and revised by MM, JRL and MMRFS; RFP and RS then conducted the literature searches, screening, data extraction, and meta-analysis, and co-wrote the manuscript; MM, JRL and MMRFS critically reviewed the manuscript and made substantive revisions prior to submission.

DATA SHARING STATEMENT

All data used to derive the outcomes presented in the study are documented in the manuscript and supplementary materials. No additional data are therefore available.

PUBLICATION RIGHTS

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

TRANSPARENCY DECLARATION

The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported. No important aspects of the study have been omitted and any discrepancies from the study as planned (and, if relevant, registered) have been explained.

ETHICAL APPROVAL

No ethical approval was required for the study as all data were derived from published data; neither animal nor human subjects were enrolled as part of the present study.

FUNDING AND STUDY SPONSOR ROLE

This study was funded by Medtronic plc following a research proposal submitted by Ossian Health Economics and Communications GmbH. The sponsor reviewed the final manuscript prior to submission, but submission was not contingent on a particular outcome of the analysis.

FINANCIAL AND COMPETING INTEREST DISCLOSURE

All authors have completed the Unified Competing Interest forms at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare:

- Michael Mestek is a full-time employee of Medtronic plc.
- Richard Pollock is a full-time employee of Ossian Health Economics and Communications GmbH, which received research and consultancy fees from Medtronic plc. to conduct the literature review and meta-analysis and prepare the manuscript.
- Rhodri Saunders was a full-time employee of Ossian Health Economics and Communications GmbH at the time of performing the meta-analysis and is currently a director of Coreva Scientific GmbH & Co. KG.
- Michel MRF Struys's research group/department received grants and funding from The Medicines Company (USA), Masimo (USA), Fresenius (Germany), Acacia Design (The Netherlands), Medtronic (USA) and honoraria from The Medicines Company (USA), Masimo (USA), Fresenius (Germany), Baxter (USA), Medtronic (USA), Demed Medical (Belgium).
- Jenifer R. Lightdale has served as a consultant for Medtronic and Norgine, and has received speaker honorarium from Mead-Johnson and Perrigo.

TABLES AND FIGURES

Table 1 Included studies reporting endpoints of interest

Study (reference)	Country	Trial dates	Modified Jadad	Potential for bias	Hospital setting	Depth of sedation	Sedative	Monitoring staff	Oxygen at baseline	N (control, Cap)
Beitz 2012 ²⁶	Germany	Feb-10, Jan-11	5.5	High: 3	Colonoscopy	"adequate"	Propofol	Not specified	2 L/minute	757 (374, 383)
Deitch 2010 ²⁴	US	Nov-06, Feb-08	5.5	Low: 0	Emergency department	Moderate	Propofol	Not specified	3 L/minute	132 (64, 68)
Friedrich-Rust 2014 ²⁷	Germany	Jun-12, May-13	6	Low: 0	Colonoscopy	Deep	Propofol+	Anesthesiologist or sedation-trained nurse	2 L/minute	533 (266, 267)
Kochhar 2015 ³⁰	US	NA	3.5	Low: 0	EGD	Moderate	Opioid and BZP	Not specified	Not specified	210 (108, 102)
Langhan 2015 ³¹	US	Sep-11, Jan-13	6	Low: 0	Pediatric emergency department	NA	Ketamine, midazolam	"Treating staff"	None	154 (77, 77)
Lightdale 2006 ⁶	US	Dec-03, Nov-04	8	Low: 0	Endoscopy	Moderate	Fentanyl, midazolam	Independent observer	2 L/minute	163 (80, 83)
Mehta 2014 ²⁸	US	NA	3.5	Low: 0	Colonoscopy	Moderate	Opioid and BZP	Not specified	Not specified	232 (115, 117)
Qadeer 2009 ⁵	US	Jan-07, May-08	7.5	Moderate: 1	ERCP and EUS	NA	Midazolam+	Independent observer	None	247 (124, 123)
Slagelse 2013 ³²	Denmark	Sep-10, Jan-11	6	Low: 0	Endoscopy	NA	Propofol	Sedation-trained nurse	2-3 L/minute	540 (277, 263)
van Loon 2014 ²⁵	Netherlands	Apr-10, Jan-11	5	Low: 0	Gynecology	Deep	Propofol	Medical team providing sedation	None	415 (209, 206)
Zongming 2014 ²⁸	China	Nov-10, May-13	6	Low: 0	Abortion	Deep	Propofol	Anesthesiologist	3 L/minute	700 (359, 341)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

+, in combination with multiple other agents; BZP, benzodiazepine; Cap, Capnography (arm); EGD, Esophagogastroduodenoscopy; ERCP, Endoscopic retrograde cholangiopancreatography; EUS, Endoscopic ultrasonography

For peer review only

1
2
3 **Figure 1 Severe and mild desaturation are reduced with capnography monitoring**
4

5 The odds ratios for the mild desaturation endpoint are presented for high-quality studies (primary analysis) for
6 severe desaturation (A) and mild desaturation (B). CI, Confidence interval; M-H, Mantel-Haenszel
7
8
9

10
11
12 **Figure 2 The need for assisted ventilation is consistently reduced with capnography**
13 **monitoring**
14

15
16
17 The odds ratios for the assisted ventilation endpoint are presented for high quality studies, which coincided with
18 all studies that reported data for the endpoint. CI, Confidence interval; M-H, Mantel-Haenszel
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Sensitivity analyses around the primary analyses, treatment effect is the odds ratio [95% confidence interval]

Scenario	Desaturation, mild	Desaturation, severe	Apnea	Bradycardia	Hypotension	Assisted ventilation	Supplemental oxygen
Base case (high quality studies)	0.54 [0.44, 0.66] RR: 0.65 [0.57, 0.74]	0.49 [0.34, 0.71] RR: 0.54 [0.39, 0.75]	0.49 [0.32, 0.75] RR: 0.68 [0.54, 0.85]	1.23 [0.87, 1.74] RR: 1.20 [0.88, 1.65]	1.03 [0.74, 1.43] RR: 1.02 [0.76, 1.37]	0.54 [0.25, 1.16] RR: 0.55 [0.26, 1.16]	0.85 [0.65, 1.11] RR: 0.89 [0.76, 1.05]
All studies with data	0.65 [0.51, 0.81]	0.47 [0.34, 0.66]	0.75 [0.43, 1.33]	1.23 [0.87, 1.74]	1.03 [0.74, 1.43]	0.54 [0.25, 1.16]	0.93 [0.65, 1.33]
Moderate sedation	0.67 [0.44, 1.04]	–	0.92 [0.52, 1.64]	–	–	–	–
US only	0.64 [0.44, 0.93]	0.35 [0.21, 0.59]	0.75 [0.43, 1.33]	–	–	–	0.82 [0.27, 2.54]
Europe only	0.65 [0.52, 0.81]	0.61 [0.40, 0.93]	–	1.46 [0.70, 3.03]	0.95 [0.64, 1.40]	0.57 [0.25, 1.29]	0.91 [0.63, 1.30]
Studies with potential bias excluded	0.69 [0.58, 0.82]	0.51 [0.28, 0.90]	0.92 [0.52, 1.64]	1.46 [0.69, 3.08]	0.95 [0.64, 1.41]	0.56 [0.25, 1.23]	1.12 [0.81, 1.55]
Studies in pediatrics excluded	0.64 [0.54, 0.75]	0.47 [0.34, 0.66]	0.79 [0.38, 1.65]	1.23 [0.87, 1.74]	1.03 [0.74, 1.43]	0.54 [0.25, 1.16]	0.90 [0.63, 1.31]
Gender-specific studies excluded	0.60 [0.50, 0.72]	0.45 [0.31, 0.63]	0.75 [0.43, 1.33]	1.23 [0.87, 1.74]	1.02 [0.71, 1.48]	0.57 [0.25, 1.29]	0.83 [0.59, 1.17]
Studies with mean age >30 years	0.59 [0.49, 0.70]	0.49 [0.33, 0.74]	0.79 [0.38, 1.65]	1.23 [0.87, 1.74]	1.03 [0.74, 1.43]	0.54 [0.25, 1.16]	0.80 [0.57, 1.14]

CI, confidence interval; OR, odds ratio; RR, risk ratio; US, United States

REFERENCES

- ¹ Sharma VK, Nguyen CC, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE. A national study of cardiopulmonary unplanned events after GI endoscopy. *Gastrointest Endosc.* 2007;66:27–34.
- ² Gangi S, Saidi F, Patel K, Johnstone B, Jaeger J, Shine D. Cardiovascular complications after GI endoscopy: occurrence and risks in a large hospital system. *Gastrointest Endosc.* 2004;60:679–85.
- ³ Erden IA, Pamuk AG, Akinci SB, Koseoglu A, Aypar U. Comparison of two ketamine-propofol dosing regimens for sedation during interventional radiology procedures. *Minerva anesthesiologica* 2010;76:260–5.
- ⁴ Lichtenstein DR, Jagannath S, Baron TH, *et al.* Sedation and anesthesia in GI endoscopy. *Gastrointest Endosc.* 2008;68:205–16.
- ⁵ Qadeer MA, Vargo JJ, Dumot JA, *et al.* Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. *Gastroenterology.* 2009;136:1568–76.
- ⁶ Lightdale JR, Goldmann DA, Feldman HA, Newburg AR, DiNardo JA, Fox VL. Microstream capnography improves patient monitoring during moderate sedation: a randomized, controlled trial. *Pediatrics.* 2006;117:e1170–8.
- ⁷ Cotton PB, Eisen GM, Aabakken L, *et al.* A lexicon for endoscopic adverse events: report of an ASGE workshop. *Gastrointest Endosc.* 2010;71:446–54.
- ⁸ Vargo JJ, Cohen LB, Rex DK, Kwo PY. Position statement: nonanesthesiologist administration of propofol for GI endoscopy. *Gastrointest Endosc.* 2009;70:1053–9.
- ⁹ Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk Factors for Hypoxemia During Ambulatory Gastrointestinal Endoscopy in ASA I-II Patients. *Dig Dis Sci.* 2009;54(5):1035–40.

- 1
2
3
4 ¹⁰ Radaelli F, Terruzzi V, Minoli G. Extended/advanced monitoring techniques in gastrointestinal
5
6 endoscopy. *Gastrointest Endosc Clin N Am*. 2004;14:335–52.
7
8
9 ¹¹ Kober A, Schubert B, Bertalanffy P, et al. Capnography in non-tracheally intubated emergency
10
11 patients as an additional tool in pulse oximetry for prehospital monitoring of respiration. *Anesth*
12
13 *Analg*. 2004;98:206–10.
14
15 ¹² Soto RG, Fu ES, Vila H, Jr., Miguel RV. Capnography accurately detects apnea during monitored
16
17 anesthesia care. *Anesth Analg*. 2004;99:379–82.
18
19
20 ¹³ Thomas PE. What's the latest on carbon dioxide monitoring? *Neonatal Netw*. 2004;23:70–2.
21
22
23 ¹⁴ Yildzdas D, Yapcoglu H, Ylmaz HL. The value of capnography during sedation or sedation/analgesia
24
25 in pediatric minor procedures. *Pediatr Emerg Care*. 2004;20:162–5.
26
27
28 ¹⁵ American Society for Gastrointestinal Endoscopy, American College of Gastroenterology,
29
30 Association TAG. Universal adoption of capnography for moderate sedation in adults undergoing
31
32 upper endoscopy and colonoscopy has not been shown to improve patient safety or clinical outcomes
33
34 and significantly increases costs for moderate sedation. Available from:
35
36 <http://www.asge.org/assets/0/71542/71544/90dc9b63-593d-48a9-bec1-9f0ab3ce946a.pdf> Last
37
38 accessed April 11, 2016.
39
40
41 ¹⁶ Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respiratory events during
42
43 procedural sedation: a meta-analysis. *J Clin Anesth*. 2011;23:189–96.
44
45
46 ¹⁷ Cook TM. The winds of change - progress in the implementation of universal capnography.
47
48 *Anaesthesia*. 2016;71(4):363–8.
49
50
51 ¹⁸ Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is
52
53 blinding necessary? *Control Clin Trials*. 1996;17(1):1–12.
54
55
56 ¹⁹ Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research
57
58 outcome and quality: systematic review. *BMJ*. 2003;326(7400):1167–70.
59
60

1
2
3
4 ²⁰ Review Manager. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark.

5
6
7 ²¹ Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*.
8
9 2003;327(7414):557–560.

10
11 ²² DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–88.

12
13
14 ²³ Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of
15
16 disease. *Journal of the National Cancer Institute* 1959;22:719–48.

17
18
19 ²⁴ Deitch K, Miner J, Chudnofsky CR, Dominici P, Latta D. Does end tidal CO2 monitoring during
20
21 emergency department procedural sedation and analgesia with propofol decrease the incidence of
22
23 hypoxic events? A randomized, controlled trial. *Ann Emerg Med*. 2010;55:258–64.

24
25
26 ²⁵ van Loon K, van Rheineck Leyssius AT, van Zaane B, Denteneer M, Kalkman CJ. Capnography during
27
28 deep sedation with propofol by nonanesthesiologists: a randomized controlled trial. *Anesth Analg*.
29
30 2014;119:49–55.

31
32
33 ²⁶ Beitz A, Riphaut A, Meining A, *et al*. Capnographic monitoring reduces the incidence of arterial
34
35 oxygen desaturation and hypoxemia during propofol sedation for colonoscopy: a randomized,
36
37 controlled study (ColoCap Study). *Am J Gastroenterol*. 2012;107:1205–12.

38
39
40 ²⁷ Friedrich-Rust M, Welte M, Welte C, *et al*. Capnographic monitoring of propofol-based sedation
41
42 during colonoscopy. *Endoscopy*. 2014;46:236–44.

43
44
45 ²⁸ Mehta P, Kochhar G, Albeldawi M, *et al*. Capnographic Monitoring Does Not Improve Detection of
46
47 Hypoxemia in Colonoscopy With Moderate Sedation: A Randomized, Controlled Trial. *Am J*
48
49 *Gastroenterol*. 2014;109:S588.

50
51 ²⁹ Zongming J, Zhonghua C, Xiangming F. Sidestream capnographic monitoring reduces the incidence
52
53 of arterial oxygen desaturation during propofol ambulatory anesthesia for surgical abortion. *Med Sci*
54
55 *Monit*. 2014;20:2336–42.
56
57
58
59
60

1
2
3
4 ³⁰ Kochhar G, Mehta PP, Kirsh B, Rizk MK, Wang Y, John B, Albeldawi M, Vargo JJ. Tu2057 Does
5
6 Capnography Prevent Hypoxemia in ASA 1-2 Outpatients Undergoing Elective EGD Targeting
7
8 Moderate Sedation? Results from a Prospective, Randomized, Single Blinded Study.
9
10 Gastroenterology;148:S-1196.

11
12
13 ³¹ Langan ML, Shabanova V, Li FY, Bernstein SL, Shapiro ED. A randomized controlled trial of
14
15 capnography during sedation in a pediatric emergency setting. Am J Emerg Med. 2015;33:25-30.

16
17
18 ³² Slagelse C, Vilmann P, Hornslet P, Jorgensen HL, Horsted TI. The role of capnography in endoscopy
19
20 patients undergoing nurse-administered propofol sedation: a randomized study. Scand J
21
22 Gastroenterol. 2013;48(10):1222-30.

23
24
25 ³³ Guimaraes ES, Campbell EJ, Richter JM. The Safety of Nurse-Administered Procedural Sedation
26
27 Compared to Anesthesia Care in a Historical Cohort of Advanced Endoscopy Patients. Anesth Analg.
28
29 2014;119(2):349-56.

30
31
32 ³⁴ Zhong B. How to Calculate Sample Size in Randomized Controlled Trial? J Thorac Dis. 2009;1(1):51-
33
34 54.

35
36
37 ³⁵ Saunders R, Erslon M, Vargo J. Modeling the costs and benefits of capnography monitoring during
38
39 procedural sedation for gastrointestinal endoscopy. Endosc Int Open. 2016;4(3):E340-51.

40
41
42 ³⁶ Berger VW and Alperson SY. A general framework for the evaluation of clinical trial quality. Rev
43
44 Recent Clin Trials. 2009;4(2):79-88.

45
46
47 ³⁷ Veerus P, Fischer K, Hakama M, Hemminki E; EPHT Trial. Results from a blind and a non-blind
48
49 randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy
50
51 (EPHT) Trial. BMC Med Res Methodol. 2012;12:44.

52
53
54 ³⁸ Klare Peter, Reiter Johanna, Meining Alexander, et al. Capnographic monitoring of midazolam and
55
56 propofol sedation during ERCP: a randomized controlled study (EndoBreath Study). Endoscopy.
57
58 2016;48:42-50.

1
2
3
4 ³⁹ Ehrenfeld JM, Funk LM, Van Schalkwyk J, Merry AF, Sandberg WS, Gawande A. The incidence of
5 hypoxemia during surgery: evidence from two institutions. *Can J Anaesth*. 2010;57(10):888–97.
6
7

8
9 ⁴⁰ Dunham CM, Hileman BM, Hutchinson AE, Chance EA, Huang GS. Perioperative hypoxemia is
10 common with horizontal positioning during general anesthesia and is associated with major adverse
11 outcomes: a retrospective study of consecutive patients. *BMC Anesthesiol*. 2014;14:43.
12
13

14
15 ⁴¹ Metzner J, Posner KL, Domino KB. The risk and safety of anesthesia at remote locations: the US
16 closed claims analysis. *Curr Opin Anaesthesiol*. 2009;22(4):502–8.
17
18

19
20 ⁴² Robbertze R, Posner KL, Domino KB. Closed claims review of anesthesia for procedures outside the
21 operating room. *Curr Opin Anaesthesiol*. 2006;19(4):436–42.
22
23

24
25 ⁴³ Cook TM, Woodall N, Harper J, Benger J. Major complications of airway management in the UK:
26 results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult
27 Airway Society. Part 2: intensive care and emergency departments. *Br J Anaesth*. 2011;106:632–42.
28
29



30
31 ⁴⁴ Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway
32 management in the UK: results of the Fourth National Audit Project of the Royal College of
33 Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. *Br J Anaesth*. 2011;106(5):632–42.
34
35
36

37
38 ⁴⁵ Campbell SG, Magee KD, Zed PJ, *et al*. End-tidal capnometry during emergency department
39 procedural sedation and analgesia: a randomized, controlled study. *World J Emerg Med*.
40 2016;7(1):13–8.
41
42
43

44
45 ⁴⁶ LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses
46 and subsequent large randomized, controlled trials. *N Engl J Med*. 1997;337(8):536–42.
47
48

49
50 ⁴⁷ Trikalinos TA, Churchill R, Ferri M, *et al*. Effect sizes in cumulative meta-analyses of mental health
51 randomized trials evolved over time. *J Clin Epidemiol*. 2004;57(11):1124–30.
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Severe and mild desaturation are reduced with capnography monitoring

Figure 1

128x78mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



The need for assisted ventilation is consistently reduced with capnography monitoring

Figure 2

56x15mm (300 x 300 DPI)

peer review only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	22
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	22
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	23
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	19,24
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	16
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	17,24-27
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	17,24-27
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	18
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	18
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

BMJ Open

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013402.R2
Article Type:	Research
Date Submitted by the Author:	08-Feb-2017
Complete List of Authors:	Saunders, Rhodri; Coreva Scientific GmbH & Co. KG. Struys, Michel; University of Groningen, Department of Anesthesiology Pollock, Richard; Ossian Health Economics and Communications GmbH, Mestek, Michael; Medtronic Inc, Patient Monitoring & Recovery Lightdale, Jenifer; UMass Memorial Children's Medical Center, Pediatric Gastroenterology
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Respiratory medicine
Keywords:	Capnography, Meta-analysis, Procedural sedation, Ambulatory surgery

SCHOLARONE™
Manuscripts

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY**MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Authors: Rhodri Saunders DPhil^{1,2}, Michel MRF Struys MD PhD FRCA³, Richard F Pollock MA MSci², Michael Mestek PhD⁴, Jenifer R Lightdale MD MPH⁵

Affiliations: ¹ Coreva Scientific GmbH & Co. KG., Freiburg, Germany
² Ossian Health Economics and Communications, Basel, Switzerland
³ Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Anesthesia, Ghent University, Ghent, Belgium
⁴ Medtronic, Patient Monitoring & Recovery, Boulder, CO
⁵ Division of Pediatric Gastroenterology, UMass Memorial Children's Medical Center, Worcester, MA; Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA

Corresponding author: Richard Pollock MA MSci
Ossian Health Economics and Communications GmbH,
Bäumleingasse 20,
4051 Basel, Switzerland
+41 61 271 62 14
pollock@ossianconsulting.com

Word count: 5,233

Running title: Patient safety during sedation: a meta-analysis

Key words: Capnography; Respiratory compromise; Oxygen desaturation; Apnea; Assisted ventilation;

Target journal: BMJ

Grant support: This study was supported by funding from Medtronic plc.

ABSTRACT

Objective

To evaluate the effect of capnography monitoring on sedation-related adverse events during procedural sedation and analgesia (PSA) administered during ambulatory surgery relative to visual assessment and pulse oximetry alone.

Design and Setting

Systematic literature review and random effects meta-analysis of randomized controlled trials (RCTs) reporting sedation-related adverse event incidence when adding capnography to visual assessment and pulse oximetry in patients undergoing PSA during ambulatory surgery in the hospital setting. Searches for eligible studies published between January 1, 1995 and December 31, 2016 (inclusive) were conducted in PubMed, the Cochrane Library and EMBASE without any language constraints. Searches were conducted in January 2017, screening and data extraction were conducted by two independent reviewers, and study quality was assessed using a modified Jadad scale.

Interventions

Capnography monitoring relative to visual assessment and pulse oximetry alone.

Primary and Secondary Outcome Measures

Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint), apnea, aspiration, bradycardia, hypotension, premature procedure termination, respiratory failure, use of assisted/bag-mask ventilation and death during PSA.

Results

The literature search identified 1,006 unique articles, of which 13 were ultimately included in the meta-analysis. Addition of capnography to visual assessment and pulse oximetry was associated with a significant reduction in mild (RR 0.77, 95% CI 0.67–0.89) and severe (RR 0.59, 95% CI 0.43–0.81)

1
2
3 desaturation, as well as in the use of assisted ventilation (RR 0.47, 95% CI 0.23–0.95). No significant
4
5 difference in other endpoints were identified.
6
7

8 **Conclusions**

9
10 Meta-analysis of 13 RCTs published between 2006 and 2016 showed a reduction in respiratory
11
12 compromise (from respiratory insufficiency to failure) during PSA with the inclusion of capnography
13
14 monitoring. In particular, use of capnography was associated with less mild and severe oxygen
15
16 desaturation, which may have helped to avoid the need for assisted ventilation.
17
18
19

20 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

21 **Strengths**

- 22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
- The studies included in the analysis were all published in 2006 or later, representing modern medical practice and providing clinically relevant evidence of improvements in patient safety with the use of capnography monitoring.
 - The study findings further substantiate a previously-published meta-analysis, which found that capnography monitoring was more likely to detect adverse events. It also suggests that superior detection may reduce the use of clinical interventions intended to rescue patients from potential adverse outcomes.

41 **Limitations**

- 42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- The level of sedation employed in each study was not uniformly reported, resulting in a mixture of different sedation levels in the primary analysis and precluding an analysis of outcomes by sedation level.
 - As with all meta-analyses, the study findings may be affected by publication, search or selection bias affecting the studies ultimately included in the analysis; however, where possible, steps were taken to minimize the effects of bias on the analysis, but the degree to which these steps were successful is difficult to quantify.

BACKGROUND AND AIMS

The administration of procedural sedation and analgesia (PSA) involves achieving a drug-induced depression in level of consciousness and pain to ensure the comfort and cooperation of patients undergoing non-surgical and minor surgical procedures. Significant adverse events associated with PSA are relatively rare but not inconsequential, and can include severe oxygen desaturation, bradycardia, hypotension, and cardiac arrest.^{1,2} Consensus dictates that levels of sedation are directly related to patient risk during PSA, as is the potential for unintended progression from moderate to deep sedation.³ Generally speaking, most cardiopulmonary events associated with PSA stem from poor or absent ventilation cascading into hypoxia, tissue injury and cardiac decompensation (Supplementary Figure 1). In turn, maintaining patient safety involves the identification of respiratory compromise to prompt the use of clinical intervention before further complications occur.^{4,5,6,7,8,9}

In current clinical practice, patient monitoring during PSA often relies on visual assessment of ventilation and use of pulse oximetry, which reflects hypoxemia.^{10,11,12,13,14} To date, a mandate to include capnography in patient monitoring, as a means of early detection of alveolar hypoventilation, has remained a topic of debate.¹⁵ In particular, there has been a perceived gap between various study outcomes and evidence of improved patient safety. No studies have provided “hard proof” that addition of capnography to patient monitoring may reduce severe morbidity and mortality during PSA (in part because of ethical considerations to ensure patient rescue). Previous efforts to use meta-analysis to determine the utility of capnography to identify clinically significant respiratory depression have been faulted for large heterogeneity and non-standard endpoints.^{16,17}

The primary aim of the present systematic review and meta-analysis was to understand whether capnography added to patient monitoring only (consisting of pulse oximetry and visual inspection of ventilation) reduces the incidence (or odds) of adverse events during PSA based on randomized controlled trials of patients undergoing a variety of surgical procedures. As a secondary aim, a power calculation was performed to determine the number of patients that would be required to

1
2
3 demonstrate a reduction in patient harm, defined as severe morbidity or mortality, in a prospective
4 clinical trial of capnography versus visual assessment with pulse oximetry. The analysis was based on
5 the hypothesis that earlier and more sensitive detection of ventilatory changes with capnography may
6 allow for more timely intervention and prevention of potential adverse events, such as cardiac
7 dysrhythmias. Throughout the analyses, we sought to provide the highest level of synthesized
8 evidence with respect to the clinical utility of capnography monitoring during PSA. To mitigate
9 potential pitfalls due to non-standard endpoints, particular emphasis was placed on maintaining a
10 consistent definition of adverse events across all studies included.
11
12
13
14
15
16
17
18
19

20 21 **METHODS**

22
23 Literature searches were conducted in PubMed, the Cochrane Library and EMBASE. Search terms were
24 a combination of Medical Subject Heading (MeSH) terms and free-text searches within the articles title
25 and abstract. Searches aimed to identify all literature reporting on randomized, controlled trials in
26 patients receiving sedation during ambulatory surgery and in which visual assessment of ventilation
27 and pulse oximetry monitoring (control) was compared with control plus capnography. "Grey" or
28 unpublished literature (including congress abstracts) was included in the search strategy and, as the
29 review protocol was not registered in advance, the full search strategy (Supplementary Table 1) and
30 additional details are provided in the Supplement. Only articles or abstracts published on or after
31 January 1, 1995 were included and all searches were performed on January 15, 2017. A previous
32 systematic review in this area did not identify any study prior to 1995,¹⁶ and studies published prior to
33 1995 were considered unlikely to reflect modern clinical practice. No language exclusion was applied
34 and inclusion was not dependent on the capnography monitor in use. After duplicate removal, title
35 and abstract screening (Supplementary Table 2) was performed independently by RS and RFP using
36 Sourcerer (Covalence Research Ltd, London UK).¹⁸ Full-text versions of all non-excluded articles were
37 retrieved by MM and reviewed independently by RS and RFP. Data were then extracted independently
38 by RS and RFP into data extraction forms in Microsoft Excel (Microsoft Corporation, Redmond, WA).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Any discrepancies in the extracted data were resolved by reference to the original study, reaching
4
5 consensus between RS and RFP. All extracted endpoint data were reviewed by JL and MMS for clinical
6
7 utility to ensure that all synthesized data relate to clinically equivalent endpoints. Extracted data
8
9 included the number of patients with events and the population at risk, in addition to items required
10
11 to assess article quality and bias. Reference lists of included studies were not searched.
12

13 14 **Endpoints**

15
16 Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint, with severe
17
18 desaturation defined as $SpO_2 \leq 85\%$), apnea, aspiration, bradycardia, hypotension, premature
19
20 procedure termination, respiratory failure, use of assisted/bag-mask ventilation and death during PSA.
21
22 The protocol was left open for the analysis of other patient safety endpoints that were reported by ≥ 3
23
24 studies. Cardiac arrest and death were considered to be representative of severe morbidity and
25
26 mortality. Notably, the present analysis examined individual endpoints as opposed to composite
27
28 endpoints (e.g. desaturation, apnea, or respiratory depression) and included analyses of more specific
29
30 endpoints, such as oxygen desaturation $< 90\%$ and $< 85\%$.
31
32
33

34 **Quality and potential bias**

35
36 Assessment of article quality was conducted on a study (as opposed to outcome) level using a
37
38 modified Jadad score,¹⁹ with additional criteria added to make the adaptation specific to monitoring.
39
40 The Jadad score assesses studies based on their design (randomized and blinded) and their reporting
41
42 (all patients accounted for), with a maximal score of 5 (high quality) and a low score of 0 (low quality).
43
44 Additional data included here were endpoint definitions, patient population, hospital location at which
45
46 patients underwent sedation, and the staff responsible for monitoring. In line with the Jadad score,
47
48 items related to trial design could score up to twice as highly as items relating to trial reporting. The
49
50 reporting of the inclusion/exclusion criteria and endpoint definitions scored one point each, and
51
52 reporting the location of sedation, and the monitoring staff scored half-point point each, making the
53
54 maximal score 8 (high quality). For the purposes of analyzing study quality, studies with scores of 0–
55
56
57
58
59
60

1
2
3 5.5 were considered to be low quality, while studies scoring 6.0–8.0 were designated as high-quality
4
5 studies.

6
7 Risk of bias in results was evaluated independently from the quality assessment through the
8
9 declaration of funding sources and conflicts of interest. If the study was funded by industry then the
10
11 study scored 2, any conflicts of interest declared relating to industry funding outside of the current
12
13 research publication scored 1. A study with low potential for bias, therefore, would have a score of 0. A
14
15 high potential for bias was defined as a score of 3, while a score of 1–2 was considered to indicate
16
17 moderate potential for bias. The absence of industry funding was not taken to signify an absence of
18
19 bias, but the presence of industry funding or conflicts of interest was assumed to be an indicator of
20
21 bias.²⁰
22
23

24 25 **Analysis**

26
27 Data extraction, initial data consolidation and summary statistics were performed in Microsoft Excel.
28
29 Data for each endpoint were subsequently entered into Review Manager 5.3.4 for results synthesis.²¹
30
31 Heterogeneity of data was evaluated using Chi^2 and I^2 statistics presented by Review Manager 5.3.4,
32
33 with I^2 further categorized by the tentative Higgins *et al.* heterogeneity categories of: low, moderate
34
35 and high.²² The meta-analysis performed calculated the mean intervention effect across all eligible
36
37 studies using (after analysis of heterogeneity) a random effects model as described by DerSimonian
38
39 and Laird.²³ An estimate of between-study variation was provided by the Mantel-Haenszel
40
41 methodology.²⁴ The main outcome reported for each endpoint is the pooled mean risk ratio (RR), with
42
43 the pooled mean odds ratio (OR) also presented. In both cases, the 95% confidence interval is
44
45 specified to allow assessment of result significance.
46
47

48
49 Sensitivity analyses were specified *a priori* and the tested conditions were: (1) inclusion of high-quality
50
51 studies only, (2) inclusion of only moderate sedation, (3) inclusion of only studies with low risk of bias,
52
53 (4) inclusion of only studies based in the US, (5) inclusion of only studies based in Europe, (6) exclusion
54
55 of pediatric data, (7) exclusion of gender-specific studies, (8) exclusion of data in patients <30 years of
56
57
58
59
60

1
2
3 age. No formal statistical comparisons were made between sensitivity analyses, and intervention
4
5 effects were not calculated for the excluded studies, thereby mitigating the introduction of type 1
6
7 error into the analysis.
8

9 10 **Patient involvement**

11
12 No patients, service users, carers or lay people were involved in the design or conduct of this study.
13
14 Outcome measures were all related to patient safety during PSA, but were not developed based on an
15
16 explicit elicitation of patient priorities, experience, and preferences.
17
18

19 20 **RESULTS**

21
22 Literature searches of PubMed, the Cochrane Library and EMBASE returned 385, 87, and 804 articles,
23
24 respectively. After removal of 270 duplicates (62 Cochrane, 208 EMBASE), 1,006 articles remained for
25
26 abstract screening. Although reasons for exclusion varied (Supplementary Table 2), the two
27
28 independent reviewers agreed upon a total of 24 articles to be retained for full-text review (Cohen's
29
30 kappa, 1.0). Eleven articles were excluded on full-text review (Supplementary Figure 2) because they:
31
32 reported duplicate data (n=5), did not report patient safety data (n=3), did not include sedation (n=2),
33
34 or compared two different capnography monitors (n=1). The 13 articles included for analysis are
35
36 presented in Table 1 and included data on 14 patient groups (one study, published by Mehta *et al.*,
37
38 provided separate data on colonoscopy and esophagogastroduodenoscopy).²⁵ All studies reported
39
40 desaturation endpoints, although the definition did vary by study (Supplementary Table 3). Other
41
42 endpoints were heterogeneously reported, but were in most cases reported by ≥ 3 studies making
43
44 meta-analysis feasible as per the pre-defined protocol. Results reported are from random-effects
45
46 models unless otherwise stated. Results for hypotension and use of supplemental oxygen are
47
48 provided in the Supplement.
49
50

51 52 53 **Mild desaturation**

54
55
56
57
58
59
60

1
2
3 All studies (Table 1) reported mild desaturation, with the definition varying from an oxygen saturation
4 (SpO₂) of <95% to <90% for ≥15 seconds.^{5,6,25,26,27,28,29,30,31,32,33,34,35} There was evidence of heterogeneity
5 (I² = 50%, moderate) in the primary analysis. Results indicated that capnography significantly reduced
6 the incidence of mild desaturation (RR 0.77, 95% CI 0.67–0.89; OR = 0.67, 95% CI 0.55–0.82; Figure 1).
7
8 The odds of a mild desaturation event were reduced by over 30% when capnography monitoring is
9 used, compared with no use of capnography. If only high-quality studies (n=7, 8 populations) were
10 included (Supplementary Figure 3), there was evidence of heterogeneity (I² = 61%, moderate) but the
11 outcome did not differ: RR 0.75 (95% CI 0.62–0.92; OR 0.63, 95% CI 0.48–0.83). Using exclusively
12 studies with equivalent definitions of mild desaturation (<90%, n=8, 9 populations), evidence of
13 heterogeneity (I² = 57%, moderate) was still present; the RR estimated from these studies was 0.76
14 (95% CI 0.65–0.89; OR 0.64, 95% CI 0.51–0.80).
15
16
17
18
19
20
21
22
23
24
25
26

27 **Severe desaturation**

28
29 Seven studies, of which four were classified as high quality, reported severe desaturation.^{5,25,27–30,34} All
30 but one of the studies defined severe desaturation as SpO₂ </≤85%. The analysis for this endpoint
31 was aligned with the significant reduction in the odds of mild desaturation with the inclusion of
32 capnography, with a RR of 0.59 (95% CI 0.43–0.81) and OR of 0.55 (95% CI 0.38–0.78). As with mild
33 desaturation, there was evidence of heterogeneity (I² = 47%, moderate).
34
35
36
37
38
39

40 Synthesizing estimates from high-quality studies supported the analysis of all studies, the RR (0.57
41 95% CI 0.36–0.92) and OR of 0.53 (95% CI 0.31–0.89) reducing by 0.02 and the confidence intervals
42 widening (Supplementary Figure 4). There was moderate heterogeneity between studies (I² = 64%,
43 moderate). Focusing on the six studies reporting an endpoint of SpO₂ </≤85%, there was moderate
44 heterogeneity and the RR was estimated at 0.56 (95% CI 0.41–0.78). Overall, a 40% reduction in the
45 incidence of severe desaturation events would be expected with the use of capnography monitoring
46 relative to standard of care.
47
48
49
50
51
52
53
54

55 **Bradycardia**

1
2
3 Six studies, three of high-quality, reported bradycardia outcomes.^{25,28–30,33,34} The definition of
4
5 bradycardia (heart rate <50 beats/minute) was consistent among five of the six trials and there was no
6
7 evidence of heterogeneity between the studies ($I^2 = 0\%$, low). In four studies, the incidence of
8
9 bradycardia was higher in the capnography arm compared with the control arm and overall,
10
11 capnography monitoring was associated with a non-significant increase in bradycardia (RR 1.15, 95%
12
13 CI 0.89–1.48; OR 1.16, 95% 0.88–1.54) and outcomes were not affected by the inclusion of only high-
14
15 quality studies or only studies with low risk of bias (Supplementary Figure 7).

16 17 18 **Apnea**

19
20 Apnea was less widely reported or reported in combination with disordered respiration. Comparable
21
22 endpoints were reported in five studies, of which three were high quality.^{5,6,25,33,34} There was
23
24 substantial heterogeneity in the apnea outcomes ($I^2 = 92\%$, high) and the analysis yielded a non-
25
26 significant RR of 1.17 (95% CI 0.72–1.89). In an analysis including exclusively high-quality studies, the
27
28 RR favored capnography but remained non-significant at 0.89 (95% CI 0.64–1.23; Supplementary
29
30 Figure 8).

31
32
33
34 There was one clear outlier in the apnea analysis, with data from Klare *et al.* 2016 reporting a RR of
35
36 11.71 (95% CI 5.30–25.90).³⁴ Apnea in this study was undefined for the standard of care arm, but in the
37
38 capnography arm the apnea criterion was the absence of exhaled CO₂ for ≥ 15 seconds. Different
39
40 criteria between trial arms may explain the large difference in detected apnea, and capnography
41
42 would be expected to detect apnea earlier than standard of care monitoring. Excluding this study from
43
44 the analysis resulted in a RR of 0.85 (95% CI 0.65–1.12; OR 0.73, 95% CI 0.43–1.24).

45 46 47 **Assisted ventilation**

48
49 Only one study reported "respiratory failure", which was treated with assisted bag-mask ventilation.²⁸
50
51 In contrast, the number of studies (n=6) reporting assisted and/or bag-mask ventilation was sufficient
52
53 to perform a meta-analysis of this endpoint as a surrogate for respiratory failure.^{5,28,29,31,32,34} Due to the
54
55 low number of events, a Peto fixed-effects odds-ratio model was used to assess this endpoint.
56
57
58
59
60

1
2
3 Analysis found no evidence of heterogeneity ($I^2 = 0\%$, low) and demonstrated a significant reduction
4
5 in assisted ventilation with capnography monitoring (OR 0.47, 95% CI 0.23–0.95). In every case, the
6
7 need to provide assisted ventilation was lower in the capnography arm compared with the control arm
8
9 (Figure 2). Three studies were of high-quality and had a low risk of bias, meta-analysis of these studies
10
11 gave an OR of 0.56 (95% CI 0.27–1.20). Three studies specified assisted ventilation as bag-mask
12
13 ventilation, and for this subset of studies the OR was 0.56 (95% CI 0.26–1.25).
14
15

16 **Sensitivity analyses**

17
18 A series of sensitivity analyses were conducted in which the studies included in the estimation of the
19
20 RR and OR were varied. The results of these analyses are presented in Table 2 and show that results
21
22 were generally robust to the studies included for data synthesis. There were limited data available to
23
24 assess the impact of capnography monitoring during moderate sedation.
25
26
27

28 **DISCUSSION**

29
30 The findings of this meta-analysis of recent RCTs comparing visual assessment of ventilation and pulse
31
32 oximetry monitoring with and without capnography during PSA showed that the odds of oxygen
33
34 desaturation and assisted ventilation events were significantly reduced with the use of capnography.
35
36 Other endpoints that could be affected by capnography monitoring were also considered but no
37
38 significant differences were detected. Of potential clinical importance, was the consistency of data
39
40 across multiple high-quality clinical trials reporting a reduced incidence of assisted ventilation with
41
42 capnography monitoring. No endpoints assessed in the meta-analysis indicated significant patient
43
44 safety concerns with capnography.
45
46
47

48
49 Physician concerns for patient safety often focus on mortality and severe morbidity. Using the need
50
51 for assisted ventilation as a proxy, there was evidence that severe morbidity may differ between
52
53 control and capnography arms in the present meta-analysis. The incidence of mortality and severe
54
55 morbidity events during nurse-administered PSA has been reported to be 1 event per 303 procedures
56
57 (0.33%).³⁶ Taking this value and using the assumption that capnography could prevent 50% of events
58
59
60

1
2
3 (in line with the estimate from our analysis) and employing trial-size estimation methodology reported
4
5 by Zhong (2009) showed that 27,726 patients would be required to demonstrate statistical
6
7 superiority.³⁷ Switching to an assumption that capnography would prevent 10% of events, the
8
9 required enrollment would be >900,000 patients. The feasibility of performing such a superiority trial
10
11 is low, leaving meta-analyses such as the present study as the only viable alternative for determining
12
13 the impact of capnography on such critical patient endpoints.
14

15
16 The analysis is timely given the ongoing debate as to whether the addition of capnography to patient
17
18 monitoring during PSA adds value.¹⁷ Without doubt, potential technical and financial burdens have
19
20 further limited adoption of capnography monitoring in various clinical settings.^{15,17} Nevertheless, it is
21
22 important to recognize that patient safety benefits may offset a number of these concerns if the
23
24 outcomes are applicable to current medical practice.³⁸ In this regard, the 13 trials identified in the
25
26 present analysis were all recent, with the first published study identified in 2006. The data used in the
27
28 meta-analysis therefore represents modern medical practice, and provides consistent evidence of
29
30 improvements in patient safety with the use of capnography monitoring.
31
32

33
34 These findings further substantiate a previously published meta-analysis (Waugh *et al.*), which found
35
36 that capnography monitoring was more likely to detect adverse events, but was faulted for large
37
38 endpoint heterogeneity.¹⁶ In the present meta-analysis, we focused on identifying high-quality studies,
39
40 and on maintaining consistent definitions across all included studies. The results show that the
41
42 addition of capnography to patient monitoring during PSA results in increased patient safety, with
43
44 significant reductions in mild and severe levels of oxygen desaturation, as well as the need for assisted
45
46 ventilation.
47

48
49 A recent meta-analysis by Conway *et al.* reported a significant benefit with capnography during
50
51 colonoscopy only with respect to hypoxemia. However, the study identified and screened only a
52
53 fraction of the literature included in the present analysis (388 papers in Conway *et al.*, compared with
54
55 1,006 papers in the current study) and retrieved fewer randomized controlled trials (6 versus 13). In
56
57 addition, Conway *et al.* excluded two trials in which an independent observer monitored capnography
58
59
60

1
2
3 output for all patients, and signaled to the attending physician when respiratory compromise was
4 identified with capnography either immediately (intervention) or after a specified delay (control).⁵⁶
5
6
7 The rationale for this study design was to prevent unnecessary patient harm while avoiding
8
9 investigator bias. Based on our understanding, the two trials excluded in the Conway *et al.* analysis
10
11 were the only studies in the literature that could be considered fully blinded. Among the other studies,
12
13 the attending physician would have been aware of study arm assignment.^{27,29,32}
14
15

16
17 As with other major assessment tools such as Delphi, Consort, and the Cochrane risk of bias tool,
18
19 blinding is an integral part of the Jadad score used in the present analysis.^{19,39} The trials excluded from
20
21 the Conway *et al.* analysis are both considered to be "high quality" in the present analysis, driven in
22
23 part by the inclusion of blinding in the scoring methodology. Other included trials, though potentially
24
25 more representative of current clinical practice, are open to operator bias, the consequences of which
26
27 were demonstrated in 2012 by Veerus *et al.*⁴⁰
28

29
30 The Jadad score is a widely used score of clinical study quality.⁴¹ In the present analysis, the scale was
31
32 modified to make it more applicable to monitoring studies by including parameters such as
33
34 monitoring staff and procedure location. One potential limitation of the present quality appraisal
35
36 approach was the lack of validation of the modifications to the Jadad score; however, as might have
37
38 been anticipated, the modified score does significantly correlate with the raw Jadad score (adjusted
39
40 $R^2 = 0.93$, $p < 0.01$). Furthermore, analysis of mild desaturation data using a mixed model that took the
41
42 Jadad score or the modified Jadad score as a covariate, found no significant difference between
43
44 models and the heterogeneity accounted for (approximately 50% for both models).
45
46

47
48 Another ongoing debate in PSA concerns the clinical importance of seemingly minor endpoints, such
49
50 as mild desaturation (oxygenation <90% for 15 seconds). Although such endpoints have traditionally
51
52 been considered transient and perhaps clinically insignificant during PSA, several recent studies of
53
54 common intraoperative events have suggested that mild desaturation may have more impact on
55
56 post-surgical outcomes than has previously been recognized.⁴² For example, Dunham *et al.* looked
57
58 retrospectively and determined that surgical patients who experienced perioperative
59
60

1
2
3 hypoxemia/desaturation had a significant increase in their length of hospital stay (+2.0 days,
4
5 $p < 0.0001$).⁴³ In turn, the impact of transient desaturation during PSA in terms of patient outcomes and
6
7 quality of life may yet be of importance but remains to be determined.
8
9

10 Over all the studies included in the analysis, there was one report of patient mortality, in the standard
11
12 of care arm of the trial presented by Klare *et al.*, 2016.³⁴ Only the largest trials reported any
13
14 requirement for assisted/bag-mask ventilation, which is used as an intervention and thereby a proxy
15
16 measure for potentially life-threatening events. Although it is generally accepted that much larger
17
18 studies would be useful to assess whether or not capnography monitoring impacts patient major
19
20 morbidity and mortality, there has been no determination of the trial size that would be required.
21
22 Power calculations suggest such a large randomized controlled trial is likely to be impractical.
23
24

25 For healthcare providers, the most significant finding may be the consistency of data surrounding
26
27 assisted ventilation and severe oxygen desaturation with capnography. Two closed claim reviews both
28
29 found that inadequate oxygenation/ventilation was the most frequent event leading to a claim related
30
31 to PSA outside the operating room.^{44,45} The potential cost burden is demonstrated by the median cost
32
33 of a claim settled being USD 330,000 (in 2007 USD).⁴⁴ The authors reported that better monitoring
34
35 would have reduced the number of claims.⁴⁴ A similar message was returned following the fourth
36
37 National Audit Project in the UK, which analyzed major complications of airway management in the
38
39 National Health Service and determined that capnography monitoring could have led to earlier
40
41 identification of airway obstruction, potentially preventing 74% of death or neurological injury
42
43 cases.^{46,47} Studies included in the present meta-analysis reported that disordered ventilation as
44
45 detected by capnography preceded desaturation events by 30 to 60 seconds.
46
47
48

49 The meta-analysis did find an increase in bradycardia with capnography monitoring that was non-
50
51 significant. However, in each of the trials reporting higher incidence the patients in the capnography
52
53 arm had larger doses and increased use of multiple agents for inducing PSA. Such confounding is
54
55 plausible, may not be unusual, and was discussed as possible factor in the trial outcomes by
56
57 Campbell *et al.* 2016.⁴⁸ All other findings of the current analysis were in line with expectations around
58
59
60

1
2
3 the potential benefits of capnography; as further substantiated by the results of our meta-analysis,
4
5 earlier identification of respiratory compromise appears to result in more timely intervention and
6
7 prevention of its escalation into patient harm.
8

9
10 As with all data synthesis projects, the present study is only as accurate and reliable as the data
11
12 underlying it. In the literature, there are examples of newly-published clinical trials that do not align
13
14 with the results of published meta-analyses, and meta-analysis results changing on the publication of
15
16 new data.^{49,50} The systematic nature of study identification and inclusion criteria in the present analysis
17
18 was designed to identify all available literature and provide the most robust estimates of intervention
19
20 effect. However, the included studies came from a variety of hospital settings, in which the rate of
21
22 patient safety events might vary. This is apparent in the clinical trial results presented by Mehta *et al.*,
23
24 where colonoscopy and esophagogastroduodenoscopy were assessed independently due to
25
26 differences in outcomes.²⁵ Analyses for particular settings were undertaken, but were then limited by
27
28 reduced data availability. In total, this analysis represented 5,460 patients (control 2,755 and
29
30 capnography 2,705) over 13 studies. Between trials, the number of patients enrolled varied between
31
32 132 and 986. Notably, of the six studies that identified rare outcomes, such as differences in use of
33
34 assisted ventilation, five enrolled >500 patients.
35
36

37 38 39 **CONCLUSIONS**

40
41 The results of this comprehensive meta-analysis of clinical trials provide clear and consistent evidence
42
43 of decreased respiratory compromise when capnography monitoring is used during procedural
44
45 sedation and analgesia (PSA). Specifically, the analysis identified a statistically significant and clinically
46
47 meaningful reduction in mild and severe oxygen desaturation, as well as in assisted ventilation. Large,
48
49 well designed, randomized controlled trials to provide direct links between use of capnography and
50
51 reduction in patient harm may not be feasible. In turn, calls for this type of primary evidence may
52
53 delay adoption of capnography monitoring during PSA as a valuable tool for early intervention and
54
55 improved patient safety.
56
57
58
59
60

1
2
3
4
5 **Word Count** 5,233
6
7
8
9

10 **AUTHOR CONTRIBUTIONS**

11
12
13
14 MM formulated the research question; RFP and RS devised the search strategy and data extraction
15 protocol, which was critically reviewed and revised by MM, JRL and MMRFS; RFP and RS then
16 conducted the literature searches, screening, data extraction, and meta-analysis, and co-wrote the
17 manuscript; MM, JRL and MMRFS critically reviewed the manuscript and made substantive revisions
18 prior to submission.
19
20
21
22
23
24

25 **DATA SHARING STATEMENT**

26
27
28
29 All data used to derive the outcomes presented in the study are documented in the manuscript and
30 supplementary materials. No additional data are therefore available.
31
32
33

34 **PUBLICATION RIGHTS**

35
36
37 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of
38 all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to
39 the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and
40 any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our
41 licence.
42
43
44
45
46
47
48

49 **TRANSPARENCY DECLARATION**

50
51
52 The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and
53 transparent account of the study being reported. No important aspects of the study have been
54
55
56
57
58
59
60

1
2
3 omitted and any discrepancies from the study as planned (and, if relevant, registered) have been
4
5 explained.
6
7

8 **ETHICAL APPROVAL**

9

10
11 No ethical approval was required for the study as all data were derived from published data; neither
12
13 animal nor human subjects were enrolled as part of the present study.
14
15

16 **FUNDING AND STUDY SPONSOR ROLE**

17

18
19 This study was funded by Medtronic plc following a research proposal submitted by Ossian Health
20
21 Economics and Communications GmbH. The sponsor reviewed the final manuscript prior to
22
23 submission, but submission was not contingent on a particular outcome of the analysis.
24
25

26 **FINANCIAL AND COMPETING INTEREST DISCLOSURE**

27

28
29 All authors have completed the Unified Competing Interest forms at www.icmje.org/coi_disclosure.pdf
30
31 (available on request from the corresponding author) and declare:
32
33

- 34 • Michael Mestek is a full-time employee of Medtronic plc.
- 35 • Richard F Pollock is a full-time employee of Ossian Health Economics and Communications GmbH,
36
37 which received research and consultancy fees from Medtronic plc. to conduct the literature review
38
39 and meta-analysis and prepare the manuscript.
40
41
- 42 • Rhodri Saunders was a full-time employee of Ossian Health Economics and Communications
43
44 GmbH at the time of performing the meta-analysis and is currently a director of Coreva Scientific
45
46 GmbH & Co. KG.
47
48
- 49 • Michel MRF Struys's research group/department received grants and funding from The Medicines
50
51 Company (USA), Masimo (USA), Fresenius (Germany), Acacia Design (The Netherlands), Medtronic
52
53 (USA) and honoraria from The Medicines Company (USA), Masimo (USA), Fresenius (Germany),
54
55 Baxter (USA), Medtronic (USA), Demed Medical (Belgium).
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
- Jenifer R Lightdale has served as a consultant for Medtronic and Norgine, and has received speaker honorarium from Mead-Johnson and Perrigo.

For peer review only

TABLES AND FIGURES

Table 1 Included studies reporting endpoints of interest

Study (reference)	Country	Trial dates	Modified Jadad †	Potential for bias	Hospital setting	Depth of sedation	Sedative	Monitoring staff	Oxygen at baseline	N (control, Cap)
Beitz 2012 ²⁸	Germany	Feb-10, Jan-11	5.5	High: 3	Colonoscopy	“adequate”	Propofol	Not specified	2 L/minute	757 (374, 383)
Deitch 2010 ²⁶	US	Nov-06, Feb-08	5.5	Low: 0	Emergency department	Moderate	Propofol	Not specified	3 L/minute	132 (64, 68)
Friedrich-Rust 2014 ²⁹	Germany	Jun-12, May-13	6	Low: 0	Colonoscopy	Deep	Propofol+	Anesthesiologist or sedation-trained nurse	2 L/minute	533 (266, 267)
Langhan 2015 ³¹	US	Sep-11, Jan-13	6	Low: 0	Pediatric emergency department	NA	Ketamine, midazolam	“Treating staff”	None	154 (77, 77)
Lightdale 2006 ⁶	US	Dec-03, Nov-04	8	Low: 0	Endoscopy	Moderate	Fentanyl, midazolam	Independent observer	2 L/minute	163 (80, 83)
Qadeer 2009 ⁵	US	Jan-07, May-08	7.5	Moderate: 1	ERCP and EUS	NA	Midazolam+	Independent observer	None	247 (124, 123)
Slagelse 2013 ³²	Denmark	Sep-10, Jan-11	6	Low: 0	Endoscopy	NA	Propofol	Sedation-trained nurse	2-3 L/minute	540 (277, 263)
van Loon 2014 ²⁷	Netherlands	Apr-10, Jan-11	5	Low: 0	Gynecology	Deep	Propofol	Medical team providing sedation	None	415 (209, 206)
Zongming 2014 ³⁰	China	Nov-10, May-13	6	Low: 0	Abortion	Deep	Propofol	Anesthesiologist	3 L/minute	700 (359, 341)
Campbell 2016	Canada	Apr-06, Apr-12	5	Moderate: 2	Emergency department	NA	Physician’s choice	Paramedic acute care practitioner	98.7% received oxygen	986 (501, 485)
Klare 2016 ³⁴	Germany	Feb-10, Oct-11	5.5	Moderate: 1	ERCP	Deep	Midazolam and	Physician not	2 L/minute	238 (117, 121)

							propofol	performing procedure		
Mehta 2016 (colon) ²⁵	US	Dec-13, Jan-15	8	Low: 0	Colonoscopy	Moderate	Fentanyl or meperidine, plus midazolam	Independent observer	None	231 (114, 117)
Mehta 2016 (EGD) ²⁵	US	Dec-13, Jan-15	8	Low: 0	EGD	Moderate	Fentanyl or meperidine, plus midazolam	Independent observer	None	209 (108, 101)
Riphaus 2016 ³³	Germany	Jun-10, Nov-11	5.5	High: 3	EUS	"adequate"	Midazolam and propofol	Independent observer	2 L/minute	170 (87, 83)

† Higher scores indicate higher quality studies. In the present analysis, a score of 6.0–8.0 was designated as high quality.

+, in combination with multiple other agents; BZP, benzodiazepine; Cap, Capnography (arm); EGD, Esophagogastroduodenoscopy; ERCP, Endoscopic retrograde cholangiopancreatography; EUS, Endoscopic ultrasonography

1
2
3 **Figure 1** **Severe and mild desaturation are significantly reduced with capnography**
4
5 **monitoring**
6

7
8 The risk ratios for the endpoints of mild desaturation (A) and severe desaturation (B) are presented. CI,
9
10 Confidence interval; M-H, Mantel-Haenszel

11
12
13
14 **Figure 2** **The need for assisted ventilation is reduced with capnography monitoring**
15

16
17]The odds ratios for the assisted ventilation endpoint are presented for all studies (A), high quality studies (B),
18
19 studies with low risk of bias (C), and studies with the end point specified as bag-mask ventilation (D). CI,
20
21 Confidence interval; M-H, Mantel-Haenszel
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Sensitivity analyses around the primary analyses

Scenario	Desaturation, mild	Desaturation, severe	Apnea	Bradycardia	Hypotension	Assisted ventilation	Supplemental oxygen
Base case (all studies)	0.77 [0.67, 0.89]	0.59 [0.43, 0.81]	1.17 [0.72, 1.89]	1.16 [0.88, 1.54]	1.02 [0.78, 1.33]	0.47 [0.23, 0.95]	0.93 [0.75, 1.15]
High quality studies	0.75 [0.62, 0.92]	0.57 [0.36, 0.92]	0.89 [0.64, 1.23]	1.26 [0.80, 1.99]	0.97 [0.73, 1.30]	0.56 [0.27, 1.20]	0.98 [0.79, 1.23]
Moderate sedation	0.80 [0.60, 1.07]	-	0.99 [0.69, 1.42]	-	-	-	-
US only	0.80 [0.64, 0.99]	0.59 [0.26, 1.30]	0.89 [0.64, 1.23]	-	1.04 [0.57, 1.88]	-	-
Europe only	0.77 [0.63, 0.96]	0.61 [0.44, 0.84]	2.83 [0.12, 67.30]	1.18 [0.86, 1.61]	0.90 [0.66, 1.24]	0.49 [0.23, 1.03]	0.91 [0.67, 1.25]
Studies with potential bias excluded	0.78 [0.64, 0.95]	0.65 [0.37, 1.14]	0.99 [0.69, 1.42]	1.26 [0.80, 1.99]	0.92 [0.68, 1.25]	0.56 [0.27, 1.20]	1.16 [0.95, 1.41]
Studies in pediatrics excluded	0.78 [0.67, 0.89]	0.59 [0.43, 0.81]	1.29 [0.75, 2.23]	1.16 [0.88, 1.54]	1.02 [0.78, 1.33]	0.47 [0.23, 0.95]	0.92 [0.74, 1.14]
Gender-specific studies excluded	0.76 [0.66, 0.89]	0.59 [0.41, 0.84]	1.17 [0.72, 1.89]	1.18 [0.84, 1.65]	1.03 [0.75, 1.41]	0.49 [0.23, 1.03]	0.84 [0.68, 1.03]
Studies with mean age >30 years	0.75 [0.65, 0.87]	0.56 [0.41, 0.78]	1.29 [0.75, 2.23]	1.16 [0.88, 1.54]	1.02 [0.78, 1.33]	0.47 [0.23, 0.95]	0.87 [0.71, 1.07]

The reported treatment effect is the relative risk (RR) [95% confidence interval], except for assisted ventilation where the peto odds ratio (OR) [95% confidence interval] is used.

CI, confidence interval; US, United States

REFERENCES

- ¹ Sharma VK, Nguyen CC, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE. A national study of cardiopulmonary unplanned events after GI endoscopy. *Gastrointest Endosc.* 2007;66:27–34.
- ² Gangi S, Saidi F, Patel K, Johnstone B, Jaeger J, Shine D. Cardiovascular complications after GI endoscopy: occurrence and risks in a large hospital system. *Gastrointest Endosc.* 2004;60:679–85.
- ³ Erden IA, Pamuk AG, Akinci SB, Koseoglu A, Aypar U. Comparison of two ketamine-propofol dosing regimens for sedation during interventional radiology procedures. *Minerva anesthesiologica* 2010;76:260–5.
- ⁴ Lichtenstein DR, Jagannath S, Baron TH, *et al.* Sedation and anesthesia in GI endoscopy. *Gastrointest Endosc.* 2008;68:205–16.
- ⁵ Qadeer MA, Vargo JJ, Dumot JA, *et al.* Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. *Gastroenterology.* 2009;136:1568–76.
- ⁶ Lightdale JR, Goldmann DA, Feldman HA, Newburg AR, DiNardo JA, Fox VL. Microstream capnography improves patient monitoring during moderate sedation: a randomized, controlled trial. *Pediatrics.* 2006;117:e1170–8.
- ⁷ Cotton PB, Eisen GM, Aabakken L, *et al.* A lexicon for endoscopic adverse events: report of an ASGE workshop. *Gastrointest Endosc.* 2010;71:446–54.
- ⁸ Vargo JJ, Cohen LB, Rex DK, Kwo PY. Position statement: nonanesthesiologist administration of propofol for GI endoscopy. *Gastrointest Endosc.* 2009;70:1053–9.
- ⁹ Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk Factors for Hypoxemia During Ambulatory Gastrointestinal Endoscopy in ASA I-II Patients. *Dig Dis Sci.* 2009;54(5):1035–40.

- 1
2
3
4 ¹⁰ Radaelli F, Terruzzi V, Minoli G. Extended/advanced monitoring techniques in gastrointestinal
5
6 endoscopy. *Gastrointest Endosc Clin N Am*. 2004;14:335–52.
7
8
9 ¹¹ Kober A, Schubert B, Bertalanffy P, et al. Capnography in non-tracheally intubated emergency
10
11 patients as an additional tool in pulse oximetry for prehospital monitoring of respiration. *Anesth*
12
13 *Analg*. 2004;98:206–10.
14
15 ¹² Soto RG, Fu ES, Vila H, Jr., Miguel RV. Capnography accurately detects apnea during monitored
16
17 anesthesia care. *Anesth Analg*. 2004;99:379–82.
18
19
20 ¹³ Thomas PE. What's the latest on carbon dioxide monitoring? *Neonatal Netw*. 2004;23:70–2.
21
22
23 ¹⁴ Yildzdas D, Yapcoglu H, Ylmaz HL. The value of capnography during sedation or sedation/analgesia
24
25 in pediatric minor procedures. *Pediatr Emerg Care*. 2004;20:162–5.
26
27
28 ¹⁵ American Society for Gastrointestinal Endoscopy, American College of Gastroenterology,
29
30 Association TAG. Universal adoption of capnography for moderate sedation in adults undergoing
31
32 upper endoscopy and colonoscopy has not been shown to improve patient safety or clinical outcomes
33
34 and significantly increases costs for moderate sedation. Available from:
35
36 <http://www.asge.org/assets/0/71542/71544/90dc9b63-593d-48a9-bec1-9f0ab3ce946a.pdf> Last
37
38 accessed April 11, 2016.
39
40
41 ¹⁶ Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respiratory events during
42
43 procedural sedation: a meta-analysis. *J Clin Anesth*. 2011;23:189–96.
44
45
46 ¹⁷ Cook TM. The winds of change - progress in the implementation of universal capnography.
47
48 *Anaesthesia*. 2016;71(4):363–8.
49
50
51 ¹⁸ Sourcerer. Covalence Research Ltd, London, UK. Available at <https://sourcerer.pro/>
52
53
54 ¹⁹ Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is
55
56 blinding necessary? *Control Clin Trials*. 1996;17(1):1–12.
57
58
59
60

- 1
2
3
4²⁰ Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research
5
6 outcome and quality: systematic review. *BMJ*. 2003;326(7400):1167–70.
7
8
9²¹ Review Manager. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark.
10
11
12²² Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*.
13
14 2003;327(7414):557–560.
15
16²³ DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–88.
17
18
19²⁴ Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of
20
21 disease. *Journal of the National Cancer Institute* 1959;22:719–48.
22
23
24²⁵ Mehta PP, Kochhar G, Albeldawi M, *et al*. Capnographic Monitoring in Routine EGD and
25
26 Colonoscopy With Moderate Sedation: A Prospective, Randomized, Controlled Trial. *Am J*
27
28 *Gastroenterol* 2016;111:395–404.
29
30²⁶ Deitch K, Miner J, Chudnofsky CR, Dominici P, Latta D. Does end tidal CO2 monitoring during
31
32 emergency department procedural sedation and analgesia with propofol decrease the incidence of
33
34 hypoxic events? A randomized, controlled trial. *Ann Emerg Med*. 2010;55:258–64.
35
36
37²⁷ van Loon K, van Rheineck Leyssius AT, van Zaane B, Denteneer M, Kalkman CJ. Capnography during
38
39 deep sedation with propofol by nonanesthesiologists: a randomized controlled trial. *Anesth Analg*.
40
41 2014;119:49–55.
42
43
44²⁸ Beitz A, Riphaus A, Meining A, *et al*. Capnographic monitoring reduces the incidence of arterial
45
46 oxygen desaturation and hypoxemia during propofol sedation for colonoscopy: a randomized,
47
48 controlled study (ColoCap Study). *Am J Gastroenterol*. 2012;107:1205–12.
49
50
51²⁹ Friedrich-Rust M, Welte M, Welte C, *et al*. Capnographic monitoring of propofol-based sedation
52
53 during colonoscopy. *Endoscopy*. 2014;46:236–44.
54
55
56
57
58
59
60

1
2
3
4 ³⁰ Zongming J, Zhonghua C, Xiangming F. Sidestream capnographic monitoring reduces the incidence
5
6 of arterial oxygen desaturation during propofol ambulatory anesthesia for surgical abortion. *Med Sci*
7
8 *Monit.* 2014;20:2336–42.
9

10
11 ³¹ Langhan ML, Shabanova V, Li FY, Bernstein SL, Shapiro ED. A randomized controlled trial of
12
13 capnography during sedation in a pediatric emergency setting. *Am J Emerg Med.* 2015;33:25–30.
14

15
16 ³² Slagelse C, Vilmann P, Hornslet P, Jorgensen HL, Horsted TI. The role of capnography in endoscopy
17
18 patients undergoing nurse-administered propofol sedation: a randomized study. *Scand J*
19
20 *Gastroenterol.* 2013;48(10):1222–30.
21

22
23 ³³ Riphaut A, Wehrmann T, Kronshage T, *et al.* Clinical value of the Integrated Pulmonary Index(®)
24
25 during sedation for interventional upper GI-endoscopy: A randomized, prospective tri-center study.
26
27 *Dig Liver Dis.* 2017;49(1):45–49.
28

29
30 ³⁴ Klare P, Reiter J, Meining A, *et al.* Capnographic monitoring of midazolam and propofol sedation
31
32 during ERCP: a randomized controlled study (EndoBreath Study). *Endoscopy.* 2016;48(1):42–50.
33

34
35 ³⁵ Campbell SG, Magee KD, Zed PJ, *et al.* End-tidal capnometry during emergency department
36
37 procedural sedation and analgesia: a randomized, controlled study. *World J Emerg Med. World J*
38
39 *Emerg Med.* 2016;7(1):13–8.
40

41
42 ³⁶ Guimaraes ES, Campbell EJ, Richter JM. The Safety of Nurse-Administered Procedural Sedation
43
44 Compared to Anesthesia Care in a Historical Cohort of Advanced Endoscopy Patients. *Anesth Analg.*
45
46 2014;119(2):349–56.
47

48
49 ³⁷ Zhong B. How to Calculate Sample Size in Randomized Controlled Trial? *J Thorac Dis.* 2009;1(1):51–
50
51 54.
52

53
54 ³⁸ Saunders R, Ersilon M, Vargo J. Modeling the costs and benefits of capnography monitoring during
55
56 procedural sedation for gastrointestinal endoscopy. *Endosc Int Open.* 2016;4(3):E340–51.
57
58
59
60

1
2
3
4 ³⁹ Berger VW and Alperson SY. A general framework for the evaluation of clinical trial quality. Rev
5 Recent Clin Trials. 2009;4(2):79–88.
6
7

8
9 ⁴⁰ Veerus P, Fischer K, Hakama M, Hemminki E; EPHT Trial. Results from a blind and a non-blind
10 randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy
11 (EPHT) Trial. BMC Med Res Methodol. 2012;12:44.
12
13

14
15 ⁴¹ Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent
16 Clin Trials. 2009;4(2):79–88.
17
18

19
20 ⁴² Ehrenfeld JM, Funk LM, Van Schalkwyk J, Merry AF, Sandberg WS, Gawande A. The incidence of
21 hypoxemia during surgery: evidence from two institutions. Can J Anaesth. 2010;57(10):888–97.
22
23

24
25 ⁴³ Dunham CM, Hileman BM, Hutchinson AE, Chance EA, Huang GS. Perioperative hypoxemia is
26 common with horizontal positioning during general anesthesia and is associated with major adverse
27 outcomes: a retrospective study of consecutive patients. BMC Anesthesiol. 2014;14:43.
28
29

30
31 ⁴⁴ Metzner J, Posner KL, Domino KB. The risk and safety of anesthesia at remote locations: the US
32 closed claims analysis. Curr Opin Anaesthesiol. 2009;22(4):502–8.
33
34

35
36 ⁴⁵ Robbertze R, Posner KL, Domino KB. Closed claims review of anesthesia for procedures outside the
37 operating room. Curr Opin Anaesthesiol. 2006;19(4):436–42.
38
39


40
41 ⁴⁶ Cook TM, Woodall N, Harper J, Benger J. Major complications of airway management in the UK:
42 results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult
43 Airway Society. Part 2: intensive care and emergency departments. Br J Anaesth. 2011;106:632–42.
44
45

46
47 ⁴⁷ Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway
48 management in the UK: results of the Fourth National Audit Project of the Royal College of
49 Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. Br J Anaesth. 2011;106(5):632–42.
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4 ⁴⁸ Campbell SG, Magee KD, Zed PJ, *et al.* End-tidal capnometry during emergency department
5
6 procedural sedation and analgesia: a randomized, controlled study. *World J Emerg Med.*
7
8 2016;7(1):13–8.
9

10
11 ⁴⁹ LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses
12
13 and subsequent large randomized, controlled trials. *N Engl J Med.* 1997;337(8):536–42.
14

15
16 ⁵⁰ Trikalinos TA, Churchill R, Ferri M, *et al.* Effect sizes in cumulative meta-analyses of mental health
17
18 randomized trials evolved over time. *J Clin Epidemiol.* 2004;57(11):1124–30.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Severe and mild desaturation are significantly reduced with capnography monitoring
 Figure 1
 205x132mm (300 x 300 DPI)



The need for assisted ventilation is reduced with capnography monitoring
 Figure 2
 205x152mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	22
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	22
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	23
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	19,24
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	16
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	17,24-27
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	17,24-27
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	18
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	18
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

BMJ Open

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013402.R3
Article Type:	Research
Date Submitted by the Author:	22-Mar-2017
Complete List of Authors:	Saunders, Rhodri; Coreva Scientific GmbH & Co. KG. Struys, Michel; University of Groningen, Department of Anesthesiology Pollock, Richard; Ossian Health Economics and Communications GmbH, Mestek, Michael; Medtronic Inc, Patient Monitoring & Recovery Lightdale, Jenifer; UMass Memorial Children's Medical Center, Pediatric Gastroenterology
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Respiratory medicine
Keywords:	Capnography, Meta-analysis, Procedural sedation, Ambulatory surgery

SCHOLARONE™
Manuscripts

PATIENT SAFETY DURING PROCEDURAL SEDATION USING CAPNOGRAPHY**MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Authors: Rhodri Saunders DPhil^{1,2}, Michel MRF Struys MD PhD FRCA³, Richard F Pollock MA MSci², Michael Mestek PhD⁴, Jenifer R Lightdale MD MPH⁵

Affiliations: ¹ Coreva Scientific GmbH & Co. KG., Freiburg, Germany
² Ossian Health Economics and Communications, Basel, Switzerland
³ Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Anesthesia, Ghent University, Gent, Belgium
⁴ Medtronic, Patient Monitoring & Recovery, Boulder, CO
⁵ Division of Pediatric Gastroenterology, UMass Memorial Children's Medical Center, Worcester, MA; Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA

Corresponding author: Richard Pollock MA MSci
Ossian Health Economics and Communications GmbH,
Bäumleingasse 20,
4051 Basel, Switzerland
+41 61 271 62 14
pollock@ossianconsulting.com

Word count: 5,233

Running title: Patient safety during sedation: a meta-analysis

Key words: Capnography; Respiratory compromise; Oxygen desaturation; Apnea; Assisted ventilation;

Target journal: BMJ

Grant support: This study was supported by funding from Medtronic plc.

ABSTRACT

Objective

To evaluate the effect of capnography monitoring on sedation-related adverse events during procedural sedation and analgesia (PSA) administered for ambulatory surgery relative to visual assessment and pulse oximetry alone.

Design and Setting

Systematic literature review and random effects meta-analysis of randomized controlled trials (RCTs) reporting sedation-related adverse event incidence when adding capnography to visual assessment and pulse oximetry in patients undergoing PSA during ambulatory surgery in the hospital setting. Searches for eligible studies published between January 1, 1995 and December 31, 2016 (inclusive) were conducted in PubMed, the Cochrane Library and EMBASE without any language constraints. Searches were conducted in January 2017, screening and data extraction were conducted by two independent reviewers, and study quality was assessed using a modified Jadad scale.

Interventions

Capnography monitoring relative to visual assessment and pulse oximetry alone.

Primary and Secondary Outcome Measures

Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint), apnea, aspiration, bradycardia, hypotension, premature procedure termination, respiratory failure, use of assisted/bag-mask ventilation and death during PSA.

Results

The literature search identified 1,006 unique articles, of which 13 were ultimately included in the meta-analysis. Addition of capnography to visual assessment and pulse oximetry was associated with a significant reduction in mild (risk ratio [RR] 0.77, 95% CI 0.67–0.89) and severe (RR 0.59, 95% CI 0.43–

0.81) desaturation, as well as in the use of assisted ventilation (odds ratio 0.47, 95% CI 0.23–0.95). No significant differences in other endpoints were identified.

Conclusions

Meta-analysis of 13 RCTs published between 2006 and 2016 showed a reduction in respiratory compromise (from respiratory insufficiency to failure) during PSA with the inclusion of capnography monitoring. In particular, use of capnography was associated with less mild and severe oxygen desaturation, which may have helped to avoid the need for assisted ventilation.

STRENGTHS AND LIMITATIONS OF THIS STUDY

Strengths

- The studies included in the analysis were all published in 2006 or later, representing modern medical practice and providing clinically relevant evidence of improvements in patient safety with the use of capnography monitoring.
- The study findings further substantiate a previously published meta-analysis, which found that capnography monitoring was more likely to detect adverse events. It also suggests that superior detection may reduce the use of clinical interventions intended to rescue patients from potential adverse outcomes.

Limitations

- The level of sedation employed in each study was not uniformly reported, resulting in a mixture of different sedation levels in the primary analysis and precluding an analysis of outcomes by sedation level.
- As with all meta-analyses, the study findings may be affected by publication, search or selection bias affecting the studies ultimately included in the analysis. Where possible, steps were taken to minimize the effects of bias on the analysis, but the degree to which these steps were successful is difficult to quantify.

BACKGROUND AND AIMS

The administration of procedural sedation and analgesia (PSA) involves achieving a drug-induced depression in level of consciousness and pain to ensure the comfort and cooperation of patients undergoing non-surgical and minor surgical procedures. Significant adverse events associated with PSA are relatively rare but not inconsequential, and can include severe oxygen desaturation, bradycardia, hypotension, and cardiac arrest.^{1,2} Consensus dictates that levels of sedation are directly related to patient risk during PSA, as is the potential for unintended progression from moderate to deep sedation.³ Generally speaking, most cardiopulmonary events associated with PSA stem from poor or absent ventilation cascading into hypoxia, tissue injury and cardiac decompensation (Supplementary Figure 1). In turn, maintaining patient safety involves the identification of respiratory compromise to prompt the use of clinical intervention before further complications occur.^{4,5,6,7,8,9}

In current clinical practice, patient monitoring during PSA often relies on visual assessment of ventilation and use of pulse oximetry, which reflects hypoxemia.^{10,11,12,13,14} To date, a mandate to include capnography in patient monitoring, as a means of early detection of alveolar hypoventilation, has remained a topic of debate.¹⁵ In particular, there has been a perceived gap between various study outcomes and evidence of improved patient safety. No studies have provided “hard proof” that addition of capnography to patient monitoring may reduce severe morbidity and mortality during PSA (in part because of ethical considerations to ensure patient rescue). Previous efforts to use meta-analysis to determine the utility of capnography to identify clinically significant respiratory depression have been faulted for large heterogeneity and non-standard endpoints.^{16,17}

The primary aim of the present systematic review and meta-analysis was to understand whether capnography added to patient monitoring only (consisting of pulse oximetry and visual inspection of ventilation) reduces the incidence (or odds) of adverse events during PSA based on randomized controlled trials of patients undergoing a variety of surgical procedures. The analysis was based on the hypothesis that earlier and more sensitive detection of ventilatory changes with capnography may

1
2
3 allow for more timely intervention and prevention of potential adverse events, such as cardiac
4
5 dysrhythmias. Throughout the analyses, we sought to provide the highest level of synthesized
6
7 evidence with respect to the clinical utility of capnography monitoring during PSA. To mitigate
8
9 potential pitfalls due to non-standard endpoints, particular emphasis was placed on maintaining a
10
11 consistent definition of adverse events across all studies included.
12

13 14 15 **METHODS**

16
17 Literature searches were conducted in PubMed, the Cochrane Library and EMBASE. Search terms were
18
19 a combination of Medical Subject Heading (MeSH) terms and free-text searches within the articles title
20
21 and abstract. Searches aimed to identify all literature reporting on randomized, controlled trials in
22
23 patients receiving sedation during ambulatory surgery and in which visual assessment of ventilation
24
25 and pulse oximetry monitoring (control) was compared with control plus capnography. "Grey" or
26
27 unpublished literature (including congress abstracts) was included in the search strategy and, as the
28
29 review protocol was not registered in advance, the full search strategy (Supplementary Table 1) and
30
31 additional details are provided in the Supplement. Only articles or abstracts published on or after
32
33 January 1, 1995 were included and all searches were performed on January 15, 2017. A previous
34
35 systematic review in this area did not identify any study prior to 1995,¹⁶ and studies published prior to
36
37 1995 were considered unlikely to reflect modern clinical practice. No language exclusion was applied
38
39 and inclusion was not dependent on the capnography monitor in use. After duplicate removal, title
40
41 and abstract screening (Supplementary Table 2) was performed independently by RS and RFP using
42
43 Sourcerer (Covalence Research Ltd, London UK).¹⁸ Full-text versions of all non-excluded articles were
44
45 retrieved by MM and reviewed independently by RS and RFP. Data were then extracted independently
46
47 by RS and RFP into data extraction forms in Microsoft Excel (Microsoft Corporation, Redmond, WA).
48
49 Any discrepancies in the extracted data were resolved by reference to the original study, reaching
50
51 consensus between RS and RFP. All extracted endpoint data were reviewed by JL and MMS for clinical
52
53 utility to ensure that all synthesized data relate to clinically equivalent endpoints. Extracted data
54
55
56
57
58
59
60

1
2
3 included the number of patients with events and the population at risk, in addition to items required
4
5 to assess article quality and bias. Reference lists of included studies were not searched.
6
7

8 **Endpoints**

9
10 Predefined endpoints of interest were desaturation/hypoxemia (the primary endpoint, with severe
11
12 desaturation defined as $SpO_2 \leq 85\%$), apnea, aspiration, bradycardia, hypotension, premature
13
14 procedure termination, respiratory failure, use of assisted/bag-mask ventilation and death during PSA.
15
16 The protocol was left open for the analysis of other patient safety endpoints that were reported by ≥ 3
17
18 studies. Cardiac arrest and death were considered to be representative of severe morbidity and
19
20 mortality. Notably, the present analysis examined individual endpoints as opposed to composite
21
22 endpoints (e.g. desaturation, apnea, or respiratory depression) and included analyses of more specific
23
24 endpoints, such as oxygen desaturation $< 90\%$ and $< 85\%$.
25
26
27

28 **Quality and potential bias**

29
30 Assessment of article quality was conducted on a study (as opposed to outcome) level using a
31
32 modified Jadad score,¹⁹ with additional criteria added to make the adaptation specific to monitoring.
33
34 The Jadad score assesses studies based on their design (randomized and blinded) and their reporting
35
36 (all patients accounted for), with a maximal score of 5 (high quality) and a low score of 0 (low quality).
37
38 Additional data included here were endpoint definitions, patient population, hospital location at which
39
40 patients underwent sedation, and the staff responsible for monitoring. In line with the Jadad score,
41
42 items related to trial design could score up to twice as highly as items relating to trial reporting. The
43
44 reporting of the inclusion/exclusion criteria and endpoint definitions scored one point each, and
45
46 reporting the location of sedation, and the monitoring staff scored half-point point each, making the
47
48 maximal score 8 (high quality). For the purposes of analyzing study quality, studies with scores of 0–
49
50 5.5 were considered to be low quality, while studies scoring 6.0–8.0 were designated as high-quality
51
52 studies.
53
54
55
56
57
58
59
60

1
2
3 Risk of bias in results was evaluated independently from the quality assessment through the
4
5 declaration of funding sources and conflicts of interest. If the study was funded by industry then the
6
7 study scored 2, any conflicts of interest declared relating to industry funding outside of the current
8
9 research publication scored 1. A study with low potential for bias, therefore, would have a score of 0. A
10
11 high potential for bias was defined as a score of 3, while a score of 1–2 was considered to indicate
12
13 moderate potential for bias. The absence of industry funding was not taken to signify an absence of
14
15 bias, but the presence of industry funding or conflicts of interest was assumed to be an indicator of
16
17 bias.²⁰
18
19

20 21 **Analysis**

22
23 Data extraction, initial data consolidation and summary statistics were performed in Microsoft Excel.
24
25 Data for each endpoint were subsequently entered into Review Manager 5.3.4 for results synthesis.²¹
26
27 Heterogeneity of data was evaluated using Chi^2 and I^2 statistics presented by Review Manager 5.3.4,
28
29 with I^2 further categorized by the tentative Higgins *et al.* heterogeneity categories of: low, moderate
30
31 and high.²² The meta-analysis performed calculated the mean intervention effect across all eligible
32
33 studies using (after analysis of heterogeneity) a random effects model as described by DerSimonian
34
35 and Laird.²³ An estimate of between-study variation was provided by the Mantel-Haenszel
36
37 methodology.²⁴
38
39

40
41 The main outcome reported for each endpoint was the pooled mean risk ratio (RR), except when the
42
43 incidence of rare endpoints was less than 1%. In these instances, the Peto method was used as a fixed-
44
45 effects model designed specifically for analysis of rare endpoints. The Peto method only reports an
46
47 odds ratio (OR) and, to allow comparison between all endpoints analyzed, the pooled mean OR was
48
49 therefore also presented for all analyses. In all cases, the 95% confidence interval is reported to allow
50
51 assessment of significance.
52

53
54 Sensitivity analyses were specified *a priori* and the tested conditions were: (1) inclusion of high-quality
55
56 studies only, (2) inclusion of only moderate sedation, (3) inclusion of only studies with low risk of bias,
57
58
59
60

1
2
3 (4) inclusion of only studies based in the US, (5) inclusion of only studies based in Europe, (6) exclusion
4 of pediatric data, (7) exclusion of gender-specific studies, (8) exclusion of data in patients <30 years of
5 age. No formal statistical comparisons were made between sensitivity analyses, and intervention
6 effects were not calculated for the excluded studies, thereby mitigating the introduction of type 1
7 error into the analysis.
8
9
10
11
12

13 **Patient involvement**

14
15 No patients, service users, or lay people were involved in the design or conduct of this study. Outcome
16 measures were all related to patient safety during PSA, but were not developed based on an explicit
17 elicitation of patient priorities, experience, and preferences.
18
19
20
21
22

23 **RESULTS**

24
25 Literature searches of PubMed, the Cochrane Library and EMBASE returned 385, 87, and 804 articles,
26 respectively. After removal of 270 duplicates (62 Cochrane, 208 EMBASE), 1,006 articles remained for
27 abstract screening. Although reasons for exclusion varied (Supplementary Table 2), the two
28 independent reviewers agreed upon a total of 24 articles to be retained for full-text review (Cohen's
29 kappa, 1.0). Eleven articles were excluded on full-text review (Supplementary Figure 2) because they:
30 reported duplicate data (n=5), did not report patient safety data (n=3), did not include sedation (n=2),
31 or compared two different capnography monitors (n=1). The 13 articles included for analysis are
32 presented in Table 1 and included data on 14 patient groups (one study, published by Mehta *et al.*,
33 provided separate data on colonoscopy and esophagogastroduodenoscopy).²⁵ All studies reported
34 desaturation endpoints, although the definition did vary by study (Supplementary Table 3). Other
35 endpoints were heterogeneously reported, but were in most cases reported by ≥ 3 studies making
36 meta-analysis feasible as per the pre-defined protocol. Results reported are from random-effects
37 models unless otherwise stated. Results for hypotension and use of supplemental oxygen are
38 provided in the Supplement.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Mild desaturation

All studies (Table 1) reported mild desaturation, with the definition varying from an oxygen saturation (SpO₂) of <95% to <90% for ≥15 seconds.^{5,6,25,26,27,28,29,30,31,32,33,34,35} There was evidence of heterogeneity (I² = 50%, moderate) in the primary analysis. Results indicated that capnography significantly reduced the incidence of mild desaturation (RR 0.77, 95% CI 0.67–0.89; OR = 0.67, 95% CI 0.55–0.82; Figure 1). The odds of a mild desaturation event were reduced by over 30% when capnography monitoring is used, compared with no use of capnography. If only high-quality studies (n=7, 8 populations) were included (Supplementary Figure 3), there was evidence of heterogeneity (I² = 61%, moderate) but the outcome did not differ: RR 0.75 (95% CI 0.62–0.92; OR 0.63, 95% CI 0.48–0.83). Using exclusively studies with equivalent definitions of mild desaturation (<90%, n=8, 9 populations), evidence of heterogeneity (I² = 57%, moderate) was still present; the RR estimated from these studies was 0.76 (95% CI 0.65–0.89; OR 0.64, 95% CI 0.51–0.80).

Severe desaturation

Seven studies, of which four were classified as high quality, reported severe desaturation.^{5,25,27–30,34} All but one of the studies defined severe desaturation as SpO₂ </≤85%. The analysis for this endpoint was aligned with the significant reduction in the odds of mild desaturation with the inclusion of capnography, with a RR of 0.59 (95% CI 0.43–0.81) and OR of 0.55 (95% CI 0.38–0.78). As with mild desaturation, there was evidence of heterogeneity (I² = 47%, moderate).

Synthesizing estimates from high-quality studies supported the analysis of all studies, the RR (0.57 95% CI 0.36–0.92) and OR of 0.53 (95% CI 0.31–0.89) reducing by 0.02 and the confidence intervals widening (Supplementary Figure 4). There was moderate heterogeneity between studies (I² = 64%, moderate). Focusing on the six studies reporting an endpoint of SpO₂ </≤85%, there was moderate heterogeneity and the RR was estimated at 0.56 (95% CI 0.41–0.78). Overall, a 40% reduction in the incidence of severe desaturation events would be expected with the use of capnography monitoring relative to standard of care.

Bradycardia

Six studies, three of high-quality, reported bradycardia outcomes.^{25,28–30,33,34} The definition of bradycardia (heart rate <50 beats/minute) was consistent among five of the six trials and there was no evidence of heterogeneity between the studies ($I^2 = 0\%$, low). In four studies, the incidence of bradycardia was higher in the capnography arm compared with the control arm and overall, capnography monitoring was associated with a non-significant increase in bradycardia (RR 1.15, 95% CI 0.89–1.48; OR 1.16, 95% CI 0.88–1.54) and outcomes were not affected by the inclusion of only high-quality studies or only studies with low risk of bias (Supplementary Figure 7).

Apnea

Apnea was less widely reported or reported in combination with disordered respiration. Comparable endpoints were reported in five studies, of which three were high quality.^{5,6,25,33,34} There was substantial heterogeneity in the apnea outcomes ($I^2 = 92\%$, high) and the analysis yielded a non-significant RR of 1.17 (95% CI 0.72–1.89). In an analysis including exclusively high-quality studies, the RR favored capnography but remained non-significant at 0.89 (95% CI 0.64–1.23; Supplementary Figure 8).

There was one clear outlier in the apnea analysis, with data from Klare *et al.* 2016 reporting a RR of 11.71 (95% CI 5.30–25.90).³⁴ Apnea in this study was undefined for the standard of care arm, but in the capnography arm the apnea criterion was the absence of exhaled CO₂ for ≥ 15 seconds. Different criteria between trial arms may explain the large difference in detected apnea, and capnography would be expected to detect apnea earlier than standard of care monitoring. Excluding this study from the analysis resulted in a RR of 0.85 (95% CI 0.65–1.12; OR 0.73, 95% CI 0.43–1.24).

Assisted ventilation

Only one study reported “respiratory failure”, which was treated with assisted bag-mask ventilation.²⁸ In contrast, the number of studies (n=6) reporting assisted and/or bag-mask ventilation was sufficient to perform a meta-analysis of this endpoint as a surrogate for respiratory failure.^{5,28,29,31,32,34} Due to the

1
2
3 low number of events, a Peto fixed-effects odds-ratio model was used to assess this endpoint.
4
5 Analysis found no evidence of heterogeneity ($I^2 = 0\%$, low) and demonstrated a significant reduction
6
7 in assisted ventilation with capnography monitoring (OR 0.47, 95% CI 0.23–0.95). In every case, the
8
9 need to provide assisted ventilation was lower in the capnography arm compared with the control arm
10
11 (Figure 2). Three studies were of high-quality and had a low risk of bias, meta-analysis of these studies
12
13 gave an OR of 0.56 (95% CI 0.27–1.20). Three studies specified assisted ventilation as bag-mask
14
15 ventilation, and for this subset of studies the OR was 0.56 (95% CI 0.26–1.25).
16
17

18 **Sensitivity analyses**

19
20
21 A series of sensitivity analyses were conducted in which the studies included in the estimation of the
22
23 RR and OR were varied. The results of these analyses are presented in Table 2 and show that results
24
25 were generally robust to the studies included for data synthesis. There were limited data available to
26
27 assess the impact of capnography monitoring during moderate sedation.
28
29

30 **DISCUSSION**

31
32
33 The findings of this meta-analysis of recent RCTs comparing visual assessment of ventilation and pulse
34
35 oximetry monitoring with and without capnography during PSA showed that the odds of oxygen
36
37 desaturation and assisted ventilation events were significantly reduced with the use of capnography.
38
39 Other endpoints that could be affected by capnography monitoring were also considered but no
40
41 significant differences were detected. Of potential clinical importance, was the consistency of data
42
43 across multiple high-quality clinical trials reporting a reduced incidence of assisted ventilation with
44
45 capnography monitoring. No endpoints assessed in the meta-analysis indicated significant patient
46
47 safety concerns with capnography.
48
49

50
51 Physician concerns for patient safety often focus on mortality and severe morbidity. Using the need
52
53 for assisted ventilation as a proxy, there was evidence that severe morbidity may differ between
54
55 control and capnography arms in the present meta-analysis. Although we note that no single trial
56
57 showed a significant difference in this outcome, the information now exists to perform a power
58
59
60

1
2
3 calculation to determine the number of patients that would be required to be enrolled in a
4
5 prospective clinical trial to demonstrate a significant reduction in patient harm. The incidence of
6
7 mortality and severe morbidity events during nurse-administered PSA has been reported to be 1
8
9 event per 303 procedures (0.33%).³⁶ Taking this value along with the assumption that capnography
10
11 could prevent 50% of events (in line with the estimate from our analysis), and employing trial-size
12
13 estimation methodology reported by Zhong (2009) showed that 27,726 patients would be required to
14
15 demonstrate statistical superiority.³⁷ Switching to an assumption that capnography would prevent
16
17 10% of events, the required enrollment would be >900,000 patients. As such, we submit the feasibility
18
19 of performing superiority trials is low, and leaves meta-analyses, such as the present study, as the only
20
21 viable alternative for determining the impact of capnography on such critical patient endpoints.
22
23

24
25 Our analysis is timely given the ongoing debate as to whether the addition of capnography to patient
26
27 monitoring during PSA adds value.¹⁷ Without doubt, potential technical and financial burdens have
28
29 further limited adoption of capnography monitoring in various clinical settings.^{15,17} Nevertheless, it is
30
31 important to recognize that patient safety benefits may offset a number of these concerns if the
32
33 outcomes are applicable to current medical practice.³⁸ In this regard, the 13 trials identified in the
34
35 present analysis were all recent, with the first published study identified in 2006. The data used in the
36
37 present meta-analysis therefore represent modern medical practice, and provides consistent evidence
38
39 of improvements in patient safety with the use of capnography monitoring.
40
41

42
43 Our findings further substantiate a previously published meta-analysis (Waugh *et al.*), which found
44
45 that capnography monitoring was more likely to detect adverse events, but was faulted for large
46
47 endpoint heterogeneity.¹⁶ In the present meta-analysis, we focused on identifying high-quality studies,
48
49 and on maintaining consistent definitions across all included studies. The results show that the
50
51 addition of capnography to patient monitoring during PSA results in increased patient safety, with
52
53 significant reductions in mild and severe levels of oxygen desaturation, as well as the need for assisted
54
55 ventilation.
56
57
58
59
60

1
2
3 A recent meta-analysis by Conway *et al.* reported a significant benefit with capnography during
4 colonoscopy only with respect to hypoxemia. However, the present meta-analysis identified and
5 screened only a fraction of the literature included in the present analysis (388 papers in Conway *et al.*,
6 compared with 1,006 papers in the current study) and retrieved fewer randomized controlled trials (6
7 versus 13). In addition, Conway *et al.* excluded two trials in which an independent observer monitored
8 capnography output for all patients, and signaled to the attending physician when respiratory
9 compromise was identified with capnography either immediately (intervention) or after a specified
10 delay (control).⁵⁶ The rationale for this study design was to prevent unnecessary patient harm while
11 avoiding investigator bias. Based on our understanding, the two trials excluded in the Conway *et al.*
12 analysis were the only studies in the literature that could be considered fully blinded. Among the other
13 studies, the attending physician would have been aware of study arm assignment.^{27,29,32}

14
15
16
17
18
19
20
21
22
23
24
25
26
27 As with other major assessment tools such as Delphi, Consort, and the Cochrane risk of bias tool,
28 blinding is an integral part of the Jadad score used in the present analysis.^{19,39} The trials excluded from
29 the Conway *et al.* analysis are both considered to be "high quality" in the present analysis, driven in
30 part by the inclusion of blinding in the scoring methodology. Other included trials, though potentially
31 more representative of current clinical practice, are open to operator bias, the consequences of which
32 were demonstrated in 2012 by Veerus *et al.*⁴⁰

33
34
35
36
37
38
39
40 The Jadad score is a widely used score of clinical study quality.⁴¹ In the present analysis, the scale was
41 modified to make it more applicable to monitoring studies by including parameters such as
42 monitoring staff and procedure location. One potential limitation of the present quality appraisal
43 approach was the lack of validation of the modifications to the Jadad score; however, as might have
44 been anticipated, the modified score does significantly correlate with the raw Jadad score (adjusted
45 $R^2 = 0.93$, $p < 0.01$). Furthermore, analysis of mild desaturation data using a mixed model that took the
46 Jadad score or the modified Jadad score as a covariate, found no significant difference between
47 models and the heterogeneity accounted for (approximately 50% for both models).

1
2
3 Another ongoing debate in PSA concerns the clinical importance of seemingly minor endpoints, such
4 as mild desaturation (oxygenation <90% for 15 seconds). Although such endpoints have traditionally
5 been considered transient and perhaps clinically insignificant during PSA, several recent studies of
6 common intraoperative events have suggested that mild desaturation may have more impact on
7 post-surgical outcomes than has previously been recognized.⁴² For example, Dunham *et al.* looked
8 retrospectively and determined that surgical patients who experienced perioperative
9 hypoxemia/desaturation had a significant increase in their length of hospital stay (+2.0 days,
10 $p < 0.0001$).⁴³ In turn, the impact of transient desaturation during PSA in terms of patient outcomes and
11 quality of life may yet be of importance but remains to be determined.

12
13
14
15
16
17
18
19
20
21
22
23 Over all of the randomized trials included in the analysis, there was one report of patient mortality,
24 which occurred in the standard of care arm of the trial presented by Klare *et al.*, 2016.³⁴ Only the
25 largest trials reported any requirement for assisted/bag-mask ventilation, which is used as an
26 intervention and thereby a proxy measure for potentially life-threatening events. Although it is widely
27 accepted that much larger studies would be useful to assess whether or not capnography monitoring
28 impacts patient major morbidity and mortality, there has been no determination to date of the trial
29 size that would be required. Power calculations furthered by our meta-analysis suggest such a large
30 randomized controlled trial is likely to be impractical.

31
32
33
34
35
36
37
38
39
40 For healthcare providers, the most significant finding may be the consistency of data surrounding
41 assisted ventilation and severe oxygen desaturation with capnography. Two closed claim reviews both
42 found that inadequate oxygenation/ventilation was the most frequent event leading to a claim related
43 to PSA outside the operating room.^{44,45} The potential cost burden is demonstrated by the median cost
44 of a claim settled being USD 330,000 (in 2007 USD).⁴⁴ The authors reported that better monitoring
45 would have reduced the number of claims.⁴⁴ A similar message was returned following the fourth
46 National Audit Project in the UK, which analyzed major complications of airway management in the
47 National Health Service and determined that capnography monitoring could have led to earlier
48 identification of airway obstruction, potentially preventing 74% of death or neurological injury

1
2
3 cases.^{46,47} Studies included in the present meta-analysis reported that disordered ventilation as
4
5 detected by capnography preceded desaturation events by 30 to 60 seconds.
6

7
8 The meta-analysis did find an increase in bradycardia with capnography monitoring that was non-
9
10 significant. However, in each of the trials reporting higher incidence the patients in the capnography
11
12 arm had larger doses and increased use of multiple agents for inducing PSA. Such confounding is
13
14 plausible, may not be unusual, and was discussed as possible factor in the trial outcomes by
15
16 Campbell *et al.* 2016.⁴⁸ All other findings of the current analysis were in line with expectations around
17
18 the potential benefits of capnography; as further substantiated by the results of our meta-analysis,
19
20 earlier identification of respiratory compromise appears to result in more timely intervention and
21
22 prevention of its escalation into patient harm.
23

24
25 As with all data synthesis projects, the present study is only as accurate and reliable as the data
26
27 underlying it. In the literature, there are examples of newly-published clinical trials that do not align
28
29 with the results of published meta-analyses, and meta-analysis results changing on the publication of
30
31 new data.^{49,50} The systematic nature of study identification and inclusion criteria in the present analysis
32
33 was designed to identify all available literature and provide the most robust estimates of intervention
34
35 effect. However, the included studies came from a variety of hospital settings, in which the rate of
36
37 patient safety events might vary. This is apparent in the clinical trial results presented by Mehta *et al.*,
38
39 where colonoscopy and esophagogastroduodenoscopy were assessed independently due to
40
41 differences in outcomes.²⁵ Analyses for particular settings were undertaken, but were then limited by
42
43 reduced data availability. In total, this analysis represented 5,460 patients (control 2,755 and
44
45 capnography 2,705) over 13 studies. Between trials, the number of patients enrolled varied between
46
47 132 and 986. Notably, of the six studies that identified rare outcomes (e.g. use of assisted ventilation),
48
49 five enrolled >500 patients.
50
51
52
53
54
55
56
57
58
59
60

CONCLUSIONS

The results of this comprehensive meta-analysis of clinical trials provide clear and consistent evidence of decreased respiratory compromise when capnography monitoring is used during procedural sedation and analgesia (PSA). Specifically, the analysis identified a statistically significant and clinically meaningful reduction in mild and severe oxygen desaturation, as well as in assisted ventilation. Large, well-designed, randomized controlled trials to provide direct links between use of capnography and reduction in patient harm may not be feasible. In turn, calls for this type of primary evidence may delay adoption of capnography monitoring during PSA as a valuable tool for early intervention and improved patient safety.

Word Count 5,233

AUTHOR CONTRIBUTIONS

MM formulated the research question; RFP and RS devised the search strategy and data extraction protocol, which was critically reviewed and revised by MM, JRL and MMRFS; RFP and RS then conducted the literature searches, screening, data extraction, and meta-analysis, and co-wrote the manuscript; MM, JRL and MMRFS critically reviewed the manuscript and made substantive revisions prior to submission.

DATA SHARING STATEMENT

All data used to derive the outcomes presented in the study are documented in the manuscript and supplementary materials. No additional data are therefore available.

PUBLICATION RIGHTS

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

TRANSPARENCY DECLARATION

The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported. No important aspects of the study have been omitted and any discrepancies from the study as planned (and, if relevant, registered) have been explained.

ETHICAL APPROVAL

No ethical approval was required for the study as all data were derived from published data; neither animal nor human subjects were enrolled as part of the present study.

FUNDING AND STUDY SPONSOR ROLE

This study was funded by Medtronic plc following a research proposal submitted by Ossian Health Economics and Communications GmbH. The sponsor reviewed the final manuscript prior to submission, but submission was not contingent on a particular outcome of the analysis.

FINANCIAL AND COMPETING INTEREST DISCLOSURE

All authors have completed the Unified Competing Interest forms at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare:

- Michael Mestek is a full-time employee of Medtronic plc.

- Richard F Pollock is a full-time employee of Ossian Health Economics and Communications GmbH, which received research and consultancy fees from Medtronic plc. to conduct the literature review and meta-analysis and prepare the manuscript.
- Rhodri Saunders was a full-time employee of Ossian Health Economics and Communications GmbH at the time of performing the meta-analysis and is currently a director of Coreva Scientific GmbH & Co. KG.
- Michel MRF Struys's research group/department received grants and funding from The Medicines Company (USA), Masimo (USA), Fresenius (Germany), Acacia Design (The Netherlands), Medtronic (USA) and honoraria from The Medicines Company (USA), Masimo (USA), Fresenius (Germany), Baxter (USA), Medtronic (USA), Demed Medical (Belgium).
- Jenifer R Lightdale has served as a consultant for Medtronic and Norgine, and has received speaker honorarium from Mead-Johnson and Perrigo.

TABLES AND FIGURES

Table 1 Included studies reporting endpoints of interest

Study (reference)	Country	Trial dates	Modified Jadad †	Potential for bias	Hospital setting	Depth of sedation	Sedative	Monitoring staff	Oxygen at baseline	N (control, Cap)
Beitz 2012 ²⁸	Germany	Feb-10, Jan-11	5.5	High: 3	Colonoscopy	"adequate"	Propofol	Not specified	2 L/minute	757 (374, 383)
Deitch 2010 ²⁶	US	Nov-06, Feb-08	5.5	Low: 0	Emergency department	Moderate	Propofol	Not specified	3 L/minute	132 (64, 68)
Friedrich-Rust 2014 ²⁹	Germany	Jun-12, May-13	6	Low: 0	Colonoscopy	Deep	Propofol+	Anesthesiologist or sedation-trained nurse	2 L/minute	533 (266, 267)
Langhan 2015 ³¹	US	Sep-11, Jan-13	6	Low: 0	Pediatric emergency department	NA	Ketamine, midazolam	"Treating staff"	None	154 (77, 77)
Lightdale 2006 ⁶	US	Dec-03, Nov-04	8	Low: 0	Endoscopy	Moderate	Fentanyl, midazolam	Independent observer	2 L/minute	163 (80, 83)
Qadeer 2009 ⁵	US	Jan-07, May-08	7.5	Moderate: 1	ERCP and EUS	NA	Midazolam+	Independent observer	None	247 (124, 123)
Slagelse 2013 ³²	Denmark	Sep-10, Jan-11	6	Low: 0	Endoscopy	NA	Propofol	Sedation-trained nurse	2-3 L/minute	540 (277, 263)
van Loon 2014 ²⁷	Netherlands	Apr-10, Jan-11	5	Low: 0	Gynecology	Deep	Propofol	Medical team providing sedation	None	415 (209, 206)
Zongming 2014 ³⁰	China	Nov-10, May-13	6	Low: 0	Abortion	Deep	Propofol	Anesthesiologist	3 L/minute	700 (359, 341)
Campbell 2016	Canada	Apr-06, Apr-12	5	Moderate: 2	Emergency department	NA	Physician's choice	Paramedic acute care practitioner	98.7% received oxygen	986 (501, 485)
Klare 2016 ³⁴	Germany	Feb-10, Oct-11	5.5	Moderate: 1	ERCP	Deep	Midazolam and	Physician not	2 L/minute	238 (117, 121)

							propofol	performing procedure		
Mehta 2016 (colon) ²⁵	US	Dec-13, Jan-15	8	Low: 0	Colonoscopy	Moderate	Fentanyl or meperidine, plus midazolam	Independent observer	None	231 (114, 117)
Mehta 2016 (EGD) ²⁵	US	Dec-13, Jan-15	8	Low: 0	EGD	Moderate	Fentanyl or meperidine, plus midazolam	Independent observer	None	209 (108, 101)
Riphaus 2016 ³³	Germany	Jun-10, Nov-11	5.5	High: 3	EUS	"adequate"	Midazolam and propofol	Independent observer	2 L/minute	170 (87, 83)

† Higher scores indicate higher quality studies. In the present analysis, a score of 6.0–8.0 was designated as high quality.

+, in combination with multiple other agents; BZP, benzodiazepine; Cap, Capnography (arm); EGD, Esophagogastroduodenoscopy; ERCP, Endoscopic retrograde cholangiopancreatography; EUS, Endoscopic ultrasonography

1
2
3 **Figure 1** **Severe and mild desaturation are significantly reduced with capnography**
4
5 **monitoring**
6

7
8 The risk ratios for the endpoints of mild desaturation (A) and severe desaturation (B) are presented. CI,
9
10 Confidence interval; M-H, Mantel-Haenszel

11
12
13
14 **Figure 2** **The need for assisted ventilation is reduced with capnography monitoring**
15

16
17]The odds ratios for the assisted ventilation endpoint are presented for all studies (A), high quality studies (B),
18
19 studies with low risk of bias (C), and studies with the end point specified as bag-mask ventilation (D). CI,
20
21 Confidence interval; M-H, Mantel-Haenszel
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Sensitivity analyses around the primary analyses

Scenario	Desaturation, mild	Desaturation, severe	Apnea	Bradycardia	Hypotension	Assisted ventilation	Supplemental oxygen
Base case (all studies)	0.77 [0.67, 0.89]	0.59 [0.43, 0.81]	1.17 [0.72, 1.89]	1.16 [0.88, 1.54]	1.02 [0.78, 1.33]	0.47 [0.23, 0.95]	0.93 [0.75, 1.15]
High quality studies	0.75 [0.62, 0.92]	0.57 [0.36, 0.92]	0.89 [0.64, 1.23]	1.26 [0.80, 1.99]	0.97 [0.73, 1.30]	0.56 [0.27, 1.20]	0.98 [0.79, 1.23]
Moderate sedation	0.80 [0.60, 1.07]	-	0.99 [0.69, 1.42]	-	-	-	-
US only	0.80 [0.64, 0.99]	0.59 [0.26, 1.30]	0.89 [0.64, 1.23]	-	1.04 [0.57, 1.88]	-	-
Europe only	0.77 [0.63, 0.96]	0.61 [0.44, 0.84]	2.83 [0.12, 67.30]	1.18 [0.86, 1.61]	0.90 [0.66, 1.24]	0.49 [0.23, 1.03]	0.91 [0.67, 1.25]
Studies with potential bias excluded	0.78 [0.64, 0.95]	0.65 [0.37, 1.14]	0.99 [0.69, 1.42]	1.26 [0.80, 1.99]	0.92 [0.68, 1.25]	0.56 [0.27, 1.20]	1.16 [0.95, 1.41]
Studies in pediatrics excluded	0.78 [0.67, 0.89]	0.59 [0.43, 0.81]	1.29 [0.75, 2.23]	1.16 [0.88, 1.54]	1.02 [0.78, 1.33]	0.47 [0.23, 0.95]	0.92 [0.74, 1.14]
Gender-specific studies excluded	0.76 [0.66, 0.89]	0.59 [0.41, 0.84]	1.17 [0.72, 1.89]	1.18 [0.84, 1.65]	1.03 [0.75, 1.41]	0.49 [0.23, 1.03]	0.84 [0.68, 1.03]
Studies with mean age >30 years	0.75 [0.65, 0.87]	0.56 [0.41, 0.78]	1.29 [0.75, 2.23]	1.16 [0.88, 1.54]	1.02 [0.78, 1.33]	0.47 [0.23, 0.95]	0.87 [0.71, 1.07]

The reported treatment effect is the risk ratio (RR) [95% confidence interval], except for assisted ventilation where the peto odds ratio (OR) [95% confidence interval] is used. CI, confidence interval; US, United States

REFERENCES

- 1 Sharma VK, Nguyen CC, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE. A national study of cardiopulmonary unplanned events after GI endoscopy. *Gastrointest Endosc.* 2007;66:27–34.
- 2 Gangi S, Saidi F, Patel K, Johnstone B, Jaeger J, Shine D. Cardiovascular complications after GI endoscopy: occurrence and risks in a large hospital system. *Gastrointest Endosc.* 2004;60:679–85.
- 3 Erden IA, Pamuk AG, Akinci SB, Koseoglu A, Aypar U. Comparison of two ketamine-propofol dosing regimens for sedation during interventional radiology procedures. *Minerva anesthesiologica* 2010;76:260–5.
- 4 Lichtenstein DR, Jagannath S, Baron TH, *et al.* Sedation and anesthesia in GI endoscopy. *Gastrointest Endosc.* 2008;68:205–16.
- 5 Qadeer MA, Vargo JJ, Dumot JA, *et al.* Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. *Gastroenterology.* 2009;136:1568–76.
- 6 Lightdale JR, Goldmann DA, Feldman HA, Newburg AR, DiNardo JA, Fox VL. Microstream capnography improves patient monitoring during moderate sedation: a randomized, controlled trial. *Pediatrics.* 2006;117:e1170–8.
- 7 Cotton PB, Eisen GM, Aabakken L, *et al.* A lexicon for endoscopic adverse events: report of an ASGE workshop. *Gastrointest Endosc.* 2010;71:446–54.
- 8 Vargo JJ, Cohen LB, Rex DK, Kwo PY. Position statement: nonanesthesiologist administration of propofol for GI endoscopy. *Gastrointest Endosc.* 2009;70:1053–9.
- 9 Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk Factors for Hypoxemia During Ambulatory Gastrointestinal Endoscopy in ASA I-II Patients. *Dig Dis Sci.* 2009;54(5):1035–40.

- 1
2
3
4¹⁰ Radaelli F, Terruzzi V, Minoli G. Extended/advanced monitoring techniques in gastrointestinal
5
6 endoscopy. *Gastrointest Endosc Clin N Am*. 2004;14:335–52.
7
8
9¹¹ Kober A, Schubert B, Bertalanffy P, et al. Capnography in non-tracheally intubated emergency
10
11 patients as an additional tool in pulse oximetry for prehospital monitoring of respiration. *Anesth*
12
13 *Analg*. 2004;98:206–10.
14
15¹² Soto RG, Fu ES, Vila H, Jr., Miguel RV. Capnography accurately detects apnea during monitored
16
17 anesthesia care. *Anesth Analg*. 2004;99:379–82.
18
19
20¹³ Thomas PE. What's the latest on carbon dioxide monitoring? *Neonatal Netw*. 2004;23:70–2.
21
22
23¹⁴ Yildzdas D, Yapcoglu H, Ylmaz HL. The value of capnography during sedation or sedation/analgesia
24
25 in pediatric minor procedures. *Pediatr Emerg Care*. 2004;20:162–5.
26
27
28¹⁵ American Society for Gastrointestinal Endoscopy, American College of Gastroenterology,
29
30 Association TAG. Universal adoption of capnography for moderate sedation in adults undergoing
31
32 upper endoscopy and colonoscopy has not been shown to improve patient safety or clinical outcomes
33
34 and significantly increases costs for moderate sedation. Available from:
35
36 <http://www.asge.org/assets/0/71542/71544/90dc9b63-593d-48a9-bec1-9f0ab3ce946a.pdf> Last
37
38 accessed April 11, 2016.
39
40
41¹⁶ Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respiratory events during
42
43 procedural sedation: a meta-analysis. *J Clin Anesth*. 2011;23:189–96.
44
45
46¹⁷ Cook TM. The winds of change - progress in the implementation of universal capnography.
47
48 *Anaesthesia*. 2016;71(4):363–8.
49
50
51¹⁸ Sourcerer. Covalence Research Ltd, London, UK. Available at <https://sourcerer.pro/>
52
53
54¹⁹ Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is
55
56 blinding necessary? *Control Clin Trials*. 1996;17(1):1–12.
57
58
59
60

1
2
3
4 ²⁰ Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research
5
6 outcome and quality: systematic review. *BMJ*. 2003;326(7400):1167–70.
7

8
9 ²¹ Review Manager. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark.
10

11 ²² Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*.
12
13 2003;327(7414):557–560.
14

15
16 ²³ DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–88.
17

18
19 ²⁴ Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of
20
21 disease. *Journal of the National Cancer Institute* 1959;22:719–48.
22

23
24 ²⁵ Mehta PP, Kochhar G, Albeldawi M, *et al*. Capnographic Monitoring in Routine EGD and
25
26 Colonoscopy With Moderate Sedation: A Prospective, Randomized, Controlled Trial. *Am J*
27
28 *Gastroenterol* 2016;111:395–404.
29

30
31 ²⁶ Deitch K, Miner J, Chudnofsky CR, Dominici P, Latta D. Does end tidal CO2 monitoring during
32
33 emergency department procedural sedation and analgesia with propofol decrease the incidence of
34
35 hypoxic events? A randomized, controlled trial. *Ann Emerg Med*. 2010;55:258–64.
36

37
38 ²⁷ van Loon K, van Rheineck Leyssius AT, van Zaane B, Denteneer M, Kalkman CJ. Capnography during
39
40 deep sedation with propofol by nonanesthesiologists: a randomized controlled trial. *Anesth Analg*.
41
42 2014;119:49–55.
43

44
45 ²⁸ Beitz A, Riphaus A, Meining A, *et al*. Capnographic monitoring reduces the incidence of arterial
46
47 oxygen desaturation and hypoxemia during propofol sedation for colonoscopy: a randomized,
48
49 controlled study (ColoCap Study). *Am J Gastroenterol*. 2012;107:1205–12.
50

51
52 ²⁹ Friedrich-Rust M, Welte M, Welte C, *et al*. Capnographic monitoring of propofol-based sedation
53
54 during colonoscopy. *Endoscopy*. 2014;46:236–44.
55
56
57
58
59
60

1
2
3
4 ³⁰ Zongming J, Zhonghua C, Xiangming F. Sidestream capnographic monitoring reduces the incidence
5
6 of arterial oxygen desaturation during propofol ambulatory anesthesia for surgical abortion. *Med Sci*
7
8 *Monit.* 2014;20:2336–42.

9
10
11 ³¹ Langhan ML, Shabanova V, Li FY, Bernstein SL, Shapiro ED. A randomized controlled trial of
12
13 capnography during sedation in a pediatric emergency setting. *Am J Emerg Med.* 2015;33:25–30.

14
15
16 ³² Slagelse C, Vilmann P, Hornslet P, Jorgensen HL, Horsted TI. The role of capnography in endoscopy
17
18 patients undergoing nurse-administered propofol sedation: a randomized study. *Scand J*
19
20 *Gastroenterol.* 2013;48(10):1222–30.

21
22
23 ³³ Riphaut A, Wehrmann T, Kronshage T, *et al.* Clinical value of the Integrated Pulmonary Index(®)
24
25 during sedation for interventional upper GI-endoscopy: A randomized, prospective tri-center study.
26
27 *Dig Liver Dis.* 2017;49(1):45–49.

28
29
30 ³⁴ Klare P, Reiter J, Meining A, *et al.* Capnographic monitoring of midazolam and propofol sedation
31
32 during ERCP: a randomized controlled study (EndoBreath Study). *Endoscopy.* 2016;48(1):42–50.

33
34
35 ³⁵ Campbell SG, Magee KD, Zed PJ, *et al.* End-tidal capnometry during emergency department
36
37 procedural sedation and analgesia: a randomized, controlled study. *World J Emerg Med. World J*
38
39 *Emerg Med.* 2016;7(1):13–8.

40
41
42 ³⁶ Guimaraes ES, Campbell EJ, Richter JM. The Safety of Nurse-Administered Procedural Sedation
43
44 Compared to Anesthesia Care in a Historical Cohort of Advanced Endoscopy Patients. *Anesth Analg.*
45
46 2014;119(2):349–56.

47
48
49 ³⁷ Zhong B. How to Calculate Sample Size in Randomized Controlled Trial? *J Thorac Dis.* 2009;1(1):51–
50
51 54.

52
53
54 ³⁸ Saunders R, Ersilon M, Vargo J. Modeling the costs and benefits of capnography monitoring during
55
56 procedural sedation for gastrointestinal endoscopy. *Endosc Int Open.* 2016;4(3):E340–51.

1
2
3
4 ³⁹ Berger VW and Alperson SY. A general framework for the evaluation of clinical trial quality. *Rev*
5
6 *Recent Clin Trials*. 2009;4(2):79–88.

7
8
9 ⁴⁰ Veerus P, Fischer K, Hakama M, Hemminki E; EPHT Trial. Results from a blind and a non-blind
10
11 randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy
12
13 (EPHT) Trial. *BMC Med Res Methodol*. 2012;12:44.

14
15
16 ⁴¹ Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. *Rev Recent*
17
18 *Clin Trials*. 2009;4(2):79–88.

19
20
21 ⁴² Ehrenfeld JM, Funk LM, Van Schalkwyk J, Merry AF, Sandberg WS, Gawande A. The incidence of
22
23 hypoxemia during surgery: evidence from two institutions. *Can J Anaesth*. 2010;57(10):888–97.

24
25
26 ⁴³ Dunham CM, Hileman BM, Hutchinson AE, Chance EA, Huang GS. Perioperative hypoxemia is
27
28 common with horizontal positioning during general anesthesia and is associated with major adverse
29
30 outcomes: a retrospective study of consecutive patients. *BMC Anesthesiol*. 2014;14:43.

31
32
33 ⁴⁴ Metzner J, Posner KL, Domino KB. The risk and safety of anesthesia at remote locations: the US
34
35 closed claims analysis. *Curr Opin Anaesthesiol*. 2009;22(4):502–8.

36
37
38 ⁴⁵ Robbertze R, Posner KL, Domino KB. Closed claims review of anesthesia for procedures outside the
39
40 operating room. *Curr Opin Anaesthesiol*. 2006;19(4):436–42.


41
42
43 ⁴⁶ Cook TM, Woodall N, Harper J, Bengner J. Major complications of airway management in the UK:
44
45 results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult
46
47 Airway Society. Part 2: intensive care and emergency departments. *Br J Anaesth*. 2011;106:632–42.

48
49
50 ⁴⁷ Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway
51
52 management in the UK: results of the Fourth National Audit Project of the Royal College of
53
54 Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. *Br J Anaesth*. 2011;106(5):632–42.


1
2
3
4 ⁴⁸ Campbell SG, Magee KD, Zed PJ, *et al.* End-tidal capnometry during emergency department
5
6 procedural sedation and analgesia: a randomized, controlled study. *World J Emerg Med.*
7
8 2016;7(1):13–8.
9

10
11 ⁴⁹ LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses
12
13 and subsequent large randomized, controlled trials. *N Engl J Med.* 1997;337(8):536–42.
14

15
16 ⁵⁰ Trikalinos TA, Churchill R, Ferri M, *et al.* Effect sizes in cumulative meta-analyses of mental health
17
18 randomized trials evolved over time. *J Clin Epidemiol.* 2004;57(11):1124–30.
19



Severe and mild desaturation are significantly reduced with capnography monitoring
 Figure 1
 205x132mm (300 x 300 DPI)



The need for assisted ventilation is reduced with capnography monitoring
 Figure 2
 205x152mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	22
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	22
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	23
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	19,24
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	16
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	17,24-27
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	17,24-27
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	18
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	18
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.